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ABSTRACT 
Title:  To compare the dosimetry of three- linear accelerator based stereotactic 
radiotherapy (SRT) techniques Static Conformal Field (SCF), Static Conformal Arc 
(SCA) and Dynamic Conformal Arc (DCA) for Pituitary adenoma and 
Cranipharyngioma. 
Aim: To compare the dosimetric outcomes of the three linear accelerator based 
stereotactic radiotherapy techniques, Static Conformal Field (SCF), Static conformal 
Arc and Dynamic conformal arc (DCA), for the treatment of Pituitary adenoma and 
Craniopharyngioma. 
Materials and methods: Computer image sets of 20 patients who have been 
diagnosed either as Pituitary adenoma or Craniopharyngioma and treated with 
Stereotactic radiotherapy (SRT) were selected for the study. For each data set, three 
SRT plans, one each with SCF, SCA and DCA techniques were generated using Brain 
LAB, iPlan RT V.4.5.3, TPS software. The Conformity index (CI), Homogeneity 
index (HI),  Quality of coverage of the target,   Dose volume histograms for the target 
and organs at risk and the time taken to deliver treatment were compared across these 
three sets of plan.  
Results:  There were 12 patients with Pituitary adenoma and eight patients with 
Craniopharyngioma. All patients had surgical excision of the tumour prior to 
radiotherapy.  The conformity and homogeneity indices were comparable across three 
techniques.  The quality of coverage was comparable in static conformal field and 
DCA techniques, where as it is slightly inferior in static conformal arc technique. The 
organs at risk are better spared in SCF and DCA techniques compared to SCA 
technique. The time taken to deliver treatment was lesser in SCF compared to SCA 
and DCA. 
Conclusions: The Conformity Index and Homogeneity Index were comparable across 
the three plans but Quality of target coverage was superior in DCA. Dynamic 
Conformal Arc (DCA) technique was the best technique among the three in achieving 
all the indices. Doses to normal organs, Optic Chiasm and Brain stem were better 
controlled in SCF technique than SCA and DCA technique. 
1 AIMS 
To compare the dosimetry of three- linear accelerator based stereotactic radiotherapy 
(SRT) techniques Static Conformal Field (SCF), Static Conformal Arc (SCA) and 
Dynamic Conformal Arc (DCA) for Pituitary adenoma and Craniopharyngioma. 
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2 OBJECTIVES 
2.1  Primary Objectives: 
a) Dosimetric comparison of three stereotactic radiotherapy treatment techniques 
Static Conformal Field (SCF), Static Conformal Arc (SCA) and Dynamic 
Conformal Arc (DCA) for Pituitary adenoma and Craniopharyngioma. 
b) To compare the dosimetric analysis performed using DVH’s and 2D dose 
displays, RTOG Quality Assurance guidelines of SRT using Conformity Index 
(CI), Homogeneity Index (HI) and Quality of target coverage 
of the three techniques. Analysis of the plans was also performed using 
parameters like maximum dose, minimum dose and mean dose. 
2.2  Secondary Objectives: 
a) To assess the east of treatment planning, time required for delivering treatment 
and analysing the number of monitor units required to deliver intended 
treatment of the three Linear Accelerator based Stereotactic Radiotherapy 
(SRT) techniques. 
 
b) To understand the efficacy of three Linear Accelerator based Stereotactic 
Radiotherapy (SRT) techniques in reducing the dose of radiation to the brain.  
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3 HYPOTHESIS 
Linear accelerator based, Dynamic Conformal Arc (DCA) stereotactic radiotherapy is 
a better technique with improved homogeneity, conformity indices and better sparing 
of organs at risk for the treatment of Pituitary adenoma and Craniopharyngioma. 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
INTRODUCTION 
  
5 
 
4 INTRODUCTION 
Stereotactic Radiotherapy is highly précised conformal radiation therapy technique. 
The word stereotaxic or stereotactic is composed of the Greek word “stereos” meaning 
three dimensional and the Latin word “tactus” which means to touch(1). Stereotactic 
approach is used to locate the target with help of three dimensional coordinate system 
located deep within the body especially in the brain. Stereotactic method of radiation 
delivery evolved from an investigational concept in animals into a main stream 
neurosurgical procedure for the management of a wide variety of brain disorders (2). 
Stereotactic Radiosurgery was started with Gamma Knife, which was discovered by 
the Lars Leksell. Later the Linear Accelerator based Stereotactic Radiotherapy 
techniques like arc therapy and static conformal therapy were developed. Invention of 
the micro Multileaf Collimators (mMLC), development of newer treatment planning 
system software and advances in imaging techniques lead to delivery of highly 
précised conformal radiotherapy. This technique of stereotactic delivery of radiation 
uses a special immobilisation device along with three-dimensional coordinate system 
to locate and deliver radiation. In the case of SRS all of the radiation is delivered in a 
single fraction where as stereotactic radiotherapy uses multiple standard fractionation 
schedules, which has radiobiological advantage of recovery from radiation damage for 
surrounding normal tissues.  Fractionated stereotactic radiotherapy (SRT) has an 
additional advantage of irradiation of the larger tumours and tumours that are located 
closely to the eloquent areas of the brain such as optic apparatus. SRT has been 
reported as safe and effective in treating Pituitary adenoma and Craniopharyngiomas. 
Various techniques of delivering SRT have been defined in the literature(3–7). Non 
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coplanar Static Conformal Field (SCF), Static Conformal Arc (SCA) and Dynamic 
Conformal Arc (DCA) radiotherapy are the three methods of Linear Accelerator based 
SRT techniques. In SCA therapy, shape of the field aperture remains constant during 
an arc. In DCA the shape of the micro MLC is automatically adjusted to the projected 
shape of the target in beams eye view for every 10 degree increment from the gantry 
start angle till the end. The SCF plan consists of six to ten non-coplanar static fields; 
each field is individually shaped to the beams eye view projection of the target using 
microMLC. 
Dynamic Conformal arc technique is an efficient technique in delivering highly 
conformal and homogenous dose which also reduces the dose to surrounding normal 
structures in intracranial sellar and suprasellar tumours like meningiomas, pituitary 
adenoma and craniopharyngiomas(8).  
The incidence of the sellar tumours accounts for 0.73 per 100,000 person years(9). 
Sellar tumours mainly include Pituitary adenomas and Craniopharyngiomas. Tumors 
of the pituitary gland and sellar region represent approximately 10-15% of all brain 
tumors, of which pituitary adenomas are the most common(10,11). Pituitary gland is 
located in the sella turcica (hypophyseal fossa) which is a part of the sphenoid bone.  
Pituitary gland is related above to optic chiasm; patients with Pituitary adenomas can 
present with visual disturbances because of the pressure effect on the optic pathway. 
Craniopharyngiomas are the third most common intracranial tumour in children after 
gliomas and medulloblastomas(12). They account for 5 to 10 percent of all childhood 
brain tumours. These are solid or mixed solid-cystic benign tumours that arise from 
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remnants of Rathke's pouch. Pituitary adenoma and Craniopharyngiomas are in close 
proximity to the optic chiasm, tracts and brain stem. 
Medical intervention may reduce the size of the tumour of secreting Pituitary adenoma 
and decrease the function. Surgery normalises the hormonal levels quickly and 
relieves the pressure symptoms.  Radiation therapy is reserved for the patient’s with 
residual disease after the surgery or when the tumour recurs after surgery. Radiation is 
also indicated in patients who are not candidates for surgical excision due to co 
morbidities. The recommended radiation dose for non-functioning pituitary adenoma, 
functioning pituitary adenoma and craniopharyngiomas are 4500cGy, 5040cGy and 
5400cGy respectively in conventional fractionation(13,14). Normalisation of the 
hormonal levels can take months to years after the radiation therapy. 
Radiation therapy is effective in controlling the tumour growth in as high as 90-100% 
in many series regardless of the type of adenoma and technique of radiation used.  The 
toxicities related to the radiation are generally low(15). The various modalities of 
delivering radiation include two dimensional external beam radiation therapy, 
conformal radiation therapy (3DCRT), Radiosurgery (SRS), Stereotactic radiation 
therapy (SRT) or Proton beam radiation therapy. Since adenomas are mostly small, 
radiologically well circumscribed and anatomically closely related to the optic 
apparatus, these tumours attracted the use of stereotactically guided high precision 
radiotherapy. More recently many reports indicated promising outcomes with SRT 
(16). In SRT patients are immobilised with a relocatable stereotactic Gill-Thomas-
Cosman (GTC) frame and tumor localization is achieved through CT scanning using a 
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Brown-Robert-Wells (BRW) localisation system. There are three different types of 
LINAC based SRT techniques defined in the literature.(3,17,18) 
 Although data for qualitative of stereotactic techniques are available for skull base 
meningioma, optic pathway gliomas, similar comparison for the three plans for 
Pituitary adenoma and Craniopharyngioma are lacking. Moreover in these tumours the 
optic chiasm is almost lying very close or sometime it is abutted by the tumour. These 
tumours are also in close contact with brain stem posteriorly. These are some of the 
features of these tumours which necessitate highly conformed homogenous dose 
distribution in the target so as to avoid normal structures. Patients with Pituitary 
adenoma and Craniopharyngioma have excellent long term survival advantage, so 
these patients are likely to benefit from high precision radiotherapy as it may reduce 
the risk of developing late side effects. 
In our study a qualitative and a quantitative dosimetric analysis of the three 
conventional SRT techniques are compared with respect to indices of conformity and 
homogeneity, quality of coverage as proposed by RTOG and also dose to normal 
tissues with the help of dose volume histograms.  In this study we also analysed the 
volume of the brain getting low dose of radiation, 5Gy in these three techniques and 
also doses such as 6Gy, 10Gy, 20Gy and 40Gy. 
In the centres, where the patient load is high, every effort has to be made to reduce the 
time consumption for planning and treatment delivery. In this regard additional 
comparison of the techniques is made in terms of ease of planning, number of monitor 
units required to deliver a prescribed dose of radiation and time taken to deliver the 
prescribed dose. 
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5 REVIEW OF LITERATURE 
5.1 Introduction to stereotactic radiotherapy 
5.1.1 Stereotaxy 
The word stereotaxic or stereotactic is composed of the Greek word “stereos” meaning 
three dimensional and the Latin word “tactus” which means to touch(1).  Stereotactic 
approach is used to locate the target with help of three dimensional coordinate system 
located deep within the body especially in the brain.  The different terms are being 
used for the different actions performed using stereotactic methods. For example 
biopsy of a lesion in the brain using stereotactic approach is known as stereotactic 
biopsy.  Radiation delivery to the tumour using stereotactic method is known as 
Stereotactic Radiosurgery or Stereotactic Radiotherapy. 
Stereotactic Radiosurgery (SRS) and Stereotactic Radiotherapy (SRT) are types of 
external beam radiotherapy techniques to administer precisely directed, high-dose 
ionising radiation that conforms to an intracranial target to create a desired 
radiobiologic response while minimizing radiation dose to surrounding normal 
tissues(19). In stereotactic radiosurgery (SRS), radiation is delivered in a single 
fraction, where as in stereotactic radiotherapy (SRT), radiation is administered in 
multiple small fractions. 
Stereotactic radiotherapy involves daily application of a non-invasive guiding device 
for the purpose of immobilisation(20).  The stereotactic irradiation is performed in an 
attempt to reduce the dose of radiation to the surrounding normal tissue over 
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conventional radiation therapy and also to provide greater dose homogeneity to the 
target tissue. 
5.1.2 Stereotactic Radiosurgery versus Stereotactic Radiotherapy 
Both SRS and SRT are effective as an adjuvant or as a primary treatment for many 
intracranial tumours(21). Both modalities are slightly different technically, but the 
principles remain same. Both modalities are used in different clinical scenarios but 
provide safer treatment options for patients with intracranial lesions. SRS alone may 
not be suitable in all the cases, the limitations are related to many factors like tumour 
size and proximity to eloquent structures especially the optic apparatus (22,23). Many 
authors have reported better clinical outcomes using SRS for meningioma smaller 
than 3cm in size or 20ml in volume with adequate distance of about 2-4 cm from optic 
apparatus(24–26). Intracranial tumours encasing or compressing eloquent structures 
such as the optic apparatus, cranial nerves and brain stem treated with SRT will 
benefit from the radiobiological advantages of fractionation (27). 
With advent of stereotactic radiotherapy it is possible to treat large intracranial 
tumours up to about 4cm such as incompletely resected tumours and also in situations 
where the risk of resection carries high morbidity and mortality. SRS is not indicated 
in tumours larger than 4 cm, since adequate coverage could not be achieved without 
limiting the toxicity(28). SRT is a treatment option that can be used when the risk of 
SRS is high in case of tumours involving brain stem, optic pathways(29,30). Andrews, 
et al. in a study investigating the safety and efficacy of stereotactic radiotherapy as an 
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alternative therapy to surgical resection for optic nerve sheath meningiomas, 
demonstrated preservation of the vision in 92% of the patients and there was an 
improvement of the vision in 42% of the patients (31). The safety of SRT has been 
established in the treatment of optic nerve sheath meningiomas. 
Rationale for using SRT is primarily to reduce the radiation damage to the 
surrounding structures and to obtain homogenous dose distribution. Though the 
concepts  and outcomes of stereotactic radiosurgery and radiotherapy are similar in 
certain indications but the radiobiology of the both approaches is fundamentally 
different(32).  In SRS, radiation therapy leads to ischemia and perfusion injury 
because of the endothelial apoptosis, resulting in cell death. Whereas fractionated 
radiotherapy relies on a different sensitivity of the target and the surrounding normal 
tissue to the total accumulated radiation dose (33).. 
5.1.3 Advantages of fractionated stereotactic radiotherapy 
Selection of the patients for SRT differs from that of SRS,  as SRT has an advantage 
over SRS in case of tumours located very close to (<3-5mm) eloquent normal 
structures like optic nerves and chiasm as the tolerance of these structures may not 
permit delivery of high dose single fractionated radiation. The tolerance of these 
organs is limited to 8-10Gy in single fraction (30). And also SRS may not be the 
treatment of choice for bigger tumours having diameter of more than 4cm due to high 
dose of radiation that passes through large areas of normal structures (34). 
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With radiosurgery, the risk of developing Radiation Induced Optic Neuritis is 
estimated to be 0-2% if the optic apparatus is constrained to 10Gy(30). However, 
when the dose to the optic apparatus exceeds 12Gy, the risk rises rapidly and is 78% 
with doses ≥ 15Gy(30). The time interval between the fractions in SRT enables 
normal tissues to repair thorough four Rs’ of Radiobiology - Reoxygenation, 
Reassortment, Repopulation and Repair improves the treatment outcome as a 
consequence of radiobiological effect(35). 
5.2 Techniques stereotactic radiotherapy 
The technique of stereotactic radiotherapy uses the same principle as SRS in terms of 
beam shaping, use of micro multileaf collimator (mMLC), rotation of the gantry etc. 
The description of the evolution of radiosurgery applies to stereotactic radiotherapy as 
well. 
The concept of radiosurgery was introduced 4 decades ago by Lars Leksell. He 
proposed the technique of focussing multiple nonparallel beams of external beam 
radiation on an intracranial target, resulting in high dose of radiation to the target and 
low dose of radiation to the surrounding structures.  He developed Gamma knife 
which uses 201 Cobalt sources. 
An alternate radiosurgical solution, LINAC Radiosurgery was first adapted by Betti 
and Derechinsky in 1984 (36).  In 1985, Colombo, et al.,(3) described such a system 
and LINACs have subsequently been modified in various ways to achieve the 
precision and accuracy required for radiosurgical applications(37).  In 1986, first 
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system of LINAC based Stereotactic radiation technique was developed in University 
of Florida(38). Then LINAC based stereotactic technique became popular in multiple 
centres around the world as other treatments also possible with LINAC compared to 
Gamma Knife which is dedicated only for Stereotactic treatments. 
“Novalis Tx” is another commercially available technological advancement in 
delivering high precision stereotactic radiosurgery using Linear Accelerator(39). 
Novalis Tx uses robotically controlled treatment table and performs radiosurgery in a 
frameless mode, which avoids discomfort to the patient as it does not require the 
surgical placement of the frame. This technique is used for treatment of both 
intracranial and extracranial tumours. This program is designed to supplement 
conventional linear accelerators with advanced beam shaping technology and image-
guidance tool to deliver high precision radiation. 
5.3 LINAC based stereotactic radiotherapy 
LINAC based Radiosurgery technique used several collimated coplanar or non-
coplanar radiation beams on a stereotactically focussed target (3). So the multiple 
static beams or arcs, in co-planar or non-coplanar beams that converge on the target 
volume are used. 
LINAC based stereotactic radiotherapy or radiosurgery is either a modification of a 
conventional LINAC for the purpose of SRT or LINAC that is specifically designed 
for the stereotactic purpose.  LINAC has got primary and secondary collimators 
located in the head of the gantry. Additional collimators are fitted to the beam head 
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when it is used for the SRT procedure.  This system uses either narrow circular cones 
(collimators) of different size or micro multileaf collimator (mMLC) (Fig 1) to shape 
the treatment fields(40). The one with mMLC comprises computer controlled multiple 
motorized tungsten leafs, (micro multileaf collimators-mMLC) which are suited for 
shaping specific fields of therapeutic intent both in a static fashion as well as 
dynamically via leaf-movement during the treatment. This mMLC is commercially 
available in different thickness from 2.5mm to 5mm. 
 
Fig 1: Micro multileaf collimators (mMLC) shaping the field to the target(40) 
The combination of gantry and couch rotation around the patient results in a variety of 
different techniques for beam delivery and the advent of mMLC resulted in dynamic 
beam shaping, in which these MLC take the shape of the tumour in beam’s eye view 
while the gantry moves from one position to the other. 
“True beam” is a commercially available technology developed by Varian Medical 
System, which is integrated, Linear accelerator based technique, which dynamically 
synchronises imaging, motion management and positioning and treatment of the 
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patient. This technique is used for all forms of advanced radiation therapy like image 
guided radiotherapy (IGRT), SRS, Intensity Modulated Radiotherapy (IMRT) and 
Stereotactic body radiotherapy (SBRT). 
SRT techniques require three-dimensional imaging and localization techniques that 
determine the exact coordinates of the target within the body. SRT requires rigid 
immobilisation system to immobilise and carefully position the patient. This 
immobilisation technique is reproduced every day for and throughout the period of 
treatment. 
5.4 Indications for SRS and SRT: 
Stereotactic radiosurgery or radiotherapy are indicated in many intracranial disorders 
as mentioned below(41) 
 Functional disorders 
  Trigeminal neuralgia 
  Vascular malformation 
  Arteriovenous malformation 
  Cavernous malformation 
 Benign tumours 
 Meningioma 
    Pituitary adenoma 
 Craniopharyngioma 
 Vestibular schwannoma 
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 Trigeminal schwannoma 
 Jugular foramen schwannoma 
 Glomus tumor 
 Metastases (less than four in number) 
 
 Skull base tumors (42). 
 Chordoma 
 Chondrosarcoma 
5.5 Clinical indications of SRT 
Fractionated stereotactic radiotherapy is also used for most of the above mentioned 
brain tumours including benign and malignant tumours. The choice of fractionated 
stereotactic radiotherapy depends on the clinical scenario, location of the tumour and 
relationship with the neighbouring structures and clinical or therapeutic intention and 
the sensitivity of the surrounding normal organ at risk. Tumours that are less than 5cm 
and closer to the optic chiasm (2-4 cm)and brainstem, or the tumours that encase the 
optic chiasms, cranial nerves or brainstem are not treated with SRS instead these 
tumours are ideal for treatment with SRT, (22,23).  Safety and efficacy of SRT has 
been established in the case of optic nerve sheath tumours, meningiomas and other 
skull based tumours including pituitary adenoma and craniopharyngioma. SRT 
delivers radiation more homogenously with better conformity so the tumours that 
benefit from more homogenous distribution will be treated with SRT. This will benefit 
especially in skull base tumours to avoid functional morbidities (21). 
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5.6 Immobilisation system for stereotactic radiotherapy 
Primary objective of radiation therapy involves accurate delivery of the prescribed 
dose of radiation to the target while sparing the surrounding critical normal structures. 
Positioning errors may lead to inaccurate dose delivery resulting in unexpected 
outcome. Geometric accuracy of radiotherapy depends on ability of positioning 
system to reproduce same geometrical position beginning from CT simulation to the 
completion of the treatment. 
Variety of commercially available immobilisation devices are reported in the 
literature. For  stereotactic radiotherapy, relocatable Gill-Thomas-Cosman (GTC) 
head frame is used, which is a non invasive localization and immobilisation technique 
providing accuracy of patient repositioning on the order of 1 mm (43).  GTC frame 
uses the dental impression of the patient’s upper teeth (dental appliance) anteriorly, a 
headrest with an individualized occipital pad posteriorly and adjustable straps (20). 
GTC frame is fixed to the patient’s head and then rigidly to the CT scanner couch 
rigidly.  The Brown-Roberts-Wells (BRW) localiser frame (Fig 2) is clamped to the 
GTC frame. The BRW coordinate system is specified by images of nine localization 
rods (Fig 3, 4) on CT slices.   The CT images were then transported to the treatment 
planning system. 
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Fig 2: GTC frame with dental impression and occipital pad 
 
 
Fig 3: BRW localiser frame with nine rods 
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Fig 4: Position of the patient during the planning CT scan using GTC frame and 
BRW localiser 
 
The same immobilisation is used during all the fractions of radiation.  The GTC frame 
(Fig 5, 6) is fixed to the Linac Couch Mount Assembly (LCMA) during the treatment 
delivery.  The Linac Target Locator Frame (LTLF) is attached to the GTC frame for 
patient positioning. The set-up lines on the LTLF should be aligned with the treatment 
room lasers 
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Fig 5: Head frame fixed on the patient with head straps, which supports the 
weight 
 
 
Fig 6: Head frame attached to the treatment couch of the Linear Accelerator 
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5.7 Different SRT techniques: 
LINAC based SRT can be performed with different techniques, they are described 
here for the purpose of comparison of the three techniques. Initially LINAC based 
radiosurgery was started with “arc” based approach with circular collimator using a 4 
MV linear accelerator at University of Southern California in 1986(5,44). Fixed 
circular collimators with projected size of the aperture ranging from 10-40 mm, 
typically using 4-8 arcs were used.  Later multileaf collimators are used to shape the 
field depending on the target shape with advent of mMLC. 
5.7.1 Static Conformal Field (SCF) 
Selection of the static conformal fields depends on the consideration of both shape and 
location of the target as projected in the beam’s eye view (BEV). Radiation fields can 
be designed using a single or multiple isocentres in coplanar or non-coplanar field 
arrangement.  The aperture of each field is defined according to the shape of the target 
on to a plane perpendicular to the direction of the beam. Number of beams may vary 
depending upon the shape, location of the target with respect to surrounding normal 
structures and intended objective. Static conformal beams using of 5-9 numbers have 
been defined to achieve the target coverage. A margin of 2-3 mm is added during the 
planning to achieve the isodose coverage of the target(17). 
5.8 Static Conformal Arc (SCA): 
In this technique gantry moves around patient in a semi circular fashion resulting in a 
concentrated dose distribution in the target and minimal dose in the normal tissues. 
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The collimators are fixed in one of the beam’s eye view of the target and the gantry is 
rotated around the patient. Number of arcs using three to six has been defined 
depending on the location, size, shape and intent of the therapy. Arcs may be used 
either in coplanar or in non-coplanar field arrangement (3). 
5.8.1 Dynamic Conformal Arc (DCA): 
The dynamic arc approach was initiated later after invention of the mMLCs. In this 
technique the gantry rotates around the target, during the dose delivery the shape of 
the miniature MLC is automatically adjusted to the projection of the target in beams 
eye view for every 10 degree increment from the gantry start angle(7). This additional 
option of shaping the mMLC while rotating gantry may result in high gradient 
conformal dose distribution (33,34). 
5.9 Comparison of the various SRT techniques: 
Many studies compare different techniques for linac based radiosurgical procedures. 
Bourland and McCollough et al., found that conformal shaped fields using 7-11 
beams resulted in the similar dose distribution as single isocentre circular arc 
technique(5).  They also noted that, the adjacent normal structures can be easily 
shielded using conformal technique. However the peripheral dose distribution was 
higher for 7-11 field plans than for the circular fields. They further speculated that the 
dynamic MLC would make an advantage in reducing the peripheral dose. 
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Cardinale R et al. compared three stereotactic radiotherapy delivery techniques for the 
intracranial lesions using conventional linac system, non-coplanar shaped field and 
intensity modulated radiation fields(45).  They suggested that arc technique is superior 
to the conformal shaped field technique in minimising the normal brain dose for the 
irregularly shaped target. 
Solberg TD et al.,(46) made a comparison of the dynamic arc field shaping with static 
field conformal and non-coplanar circular arcs on simulated targets They have 
suggested that use of dynamic arc has an added advantage that they are simple to plan 
and fast to treat. 
Evaluation of different radiosurgery techniques for pituitary adenomas was done by 
Grabenbauer GG et al.,(47) who compared the dynamic and conformal arcs, shaped 
beams and IMRT authors concluded that dynamic arc treatment with mMLC is 
considered safe and appropriate for treatment of pituitary adenomas. 
Lee et al., conducted a study to determine the effect of static and dynamic collimator 
optimization with use of microMLC in dynamic arc stereotactic radiotherapy on thirty 
patients with intracranial tumours(48) and concluded that dynamic collimator 
optimisation technique during the arc based therapy is an effective method in reducing 
the radiation dose to the peripheral normal brain. This method was also effective in 
improving the target conformity. 
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Hamilton et a., evaluated the efficacy of static conformal fields with the use of 
multiple non-coplanar arcs for stereotactic radiosurgery or stereotactic radiotherapy in 
terms of dose delivery distribution and found that simple conformal therapy technique 
offers an advantage over multiple arc technique for SRS and SRT(49). 
Sharma et al,. (50)compared the various conventional stereotactic (SRT) techniques 
with IM-SRT in brain tumours of varying shape, size, location and proximity to the 
organs at risk (OARs). They concluded that dynamic conformal arc (DCA) and static 
conformal field (SCF) are preferred SRT techniques in terms of target conformity and 
reduction of the dose to OARs. 
5.10 Evaluation of the various SRT treatment techniques: 
Every new technique of radiotherapy aims to widen the separation of the tumour 
control probability (TCP) and normal tissue complication probability (NTCP), along 
with uniform dose distribution throughout the target volume. The prescribed dose of 
radiation has to be distributed uniformly in the target volume. 
The therapeutic advantage of high conformal radiotherapy depends on the conformity 
of the prescription dose to the planning target volume (PTV), dose homogeneity 
within the PTV, and less dose to the surrounding normal tissue and critical organs. 
The radiobiological effects and dose homogeneity are interrelated. The concept of 
equivalent uniform dose (EUD) developed by Niemierko et al., (51)is one of the 
method helps in understanding relationship between the dose homogeneity and 
radiobiological effects. The equivalent uniform dose is defined as the biologically 
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equivalent dose that, if delivered uniformly, would lead to the same reduction in the 
tumour volume as the actual dose that has an inhomogeneous distribution. 
The appropriate selection of the treatment plan depends on many factors, like dose 
distribution in the target, target coverage, presence of hot spots or cold spots and also 
the doses to the surrounding normal structures.  Modern treatment planning systems 
generate enormous amount of data like maximum dose, mean dose, minimum dose 
and dose volume histograms.  Radiation oncologist has to select the best plan based on 
information on clinical, radiologic, geometric, dosimetric, and radiobiologic 
parameters.  Analysis with these tools may be more tedious and complex in deciding 
the optimal plan for patient. It is difficult to incorporate all the data in analysing these 
tools. 
Different tools have been mentioned in the literature to analyse the radiotherapy 
treatment plan. The dose distribution in the plan can be visualized in the form of dose-
volume histograms (DVHs), parameters like maximum dose (dmax), minimum dose 
(dmin), mean dose (dmean) and modal dose delivered to each volume of interest. 
However these data may not clearly give idea in choosing the favourable plan all the 
time. RTOG guidelines used to analyse the treatment plan evaluation, by assessing the 
conformity index, homogeneity index and quality of the target coverage in addition to 
dose volume histogram. 
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5.10.1 Conformity index 
The conformity index was developed to analyse the spatial dose distribution in each 
section of the target. It quantifies the degree of congruence between tumour contours 
and isodose lines by geometric intersection methods. This tool could facilitate the 
choice of a particular treatment and comparisons can also be made with different plans 
of the same patient for stereotactic radiotherapy. (52)    
Conformity Index (RTOG) =                                                                         
Where VRI reference isodose volume, and TV target volume. 
The RTOG “conformity index” analyses the conformity based on the above 
mentioned formula. The RTOG conformity index 1 is an ideal form of conformation, 
where the reference isodose volume is exactly same as target volume. A conformity 
index greater than 1 indicates that the reference isodose volume is greater than the 
target volume; this represents irradiated volume is greater than the target volume and 
includes healthy tissues surrounding the target. If the conformity index is less than 1, 
the target volume is only partially covered by reference isodose or irradiated.  It may 
be difficult to get conformity index of 1 in practical situations and rarely achieved, so 
RTOG guidelines, defined ranges of conformity index values to determine the quality 
of conformation. 
If the conformity index is situated between 1 and 2, treatment is considered to comply 
with the treatment plan; an index between 2 and 2.5, or 0.9 and 1, is considered to be a 
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minor violation of the protocol, and an index less than 0.9 or more than 2.5 is 
considered to be a major violation of the protocol. 
5.10.2 Homogeneity index 
The concept of homogeneity index (HI) was developed to analyse the spatial dose 
distribution in each section of the treatment plan.  HI was described as, (52) 
HIRTOG =                                                                                                      
Imax = maximum isodose in the target, and RI = reference isodose. 
If the HI was ≤2, treatment was considered to comply with the protocol, if this index 
was between 2 to 2.5, it was considered as minor violation, but if the index exceeded 
2.5, the violation of the protocol was considered to be major, but might nevertheless 
considered acceptable. 
Reference isodose corresponds to either the minimum isodose volume containing the 
target volume or the 95% isodose volume according to ICRU 50 guidelines. 
5.10.3 Quality of coverage 
Quality of coverage (RTOG)   (52)                                                                                                 
Where I-min is minimum dose received by the target and RI is the reference isodose. 
As per the RTOG protocol, if the minimum dose received by the target is ≥90% of the 
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prescribed dose, the treatment is considered to be complying with protocol. If the 
minimum dose received by the target is 80-89% of the prescribed dose, the protocol is 
considered to be minor violation and if the minimum dose received by the target is 
<80% of the prescribed dose it is considered to be major protocol violation. 
5.10.4 DVH Analysis 
The large and more complex dosimetric data has to be analysed when a conformal 
plan is being evaluated and this prompted development of a tool which helps in 
understanding the frequency of dose distribution across the volume of the interest, 
known as dose volume histogram (53).  Two types of DVH have been defined; the 
differential DVH (dDVH) and the integral DVH (iDVH). They both are useful for 
assessing tumor volume coverage and the dose distribution either to healthy tissue 
surrounding the target or to specific structures in the vicinity of the target. 
The DVH is thus a powerful tool used for conformal plan evaluation. The plan can be 
analysed in terms of DVHs for PTV or PRVs and OARs.  Several plans of a same 
patient can be compared and analysed using DVH analysis. However DVH does not 
give information on the spatial dose distribution, but provides volume based 
information for summarizing and quantifying complex dose distributions. It also 
provides an accurate assessment of homogeneity in the PTV. 
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5.11 Normal tissue tolerances 
The following are the normal tissue tolerances, as defined in the Quantitative 
Analyses of Normal Tissue Effects in the Clinic (QUANTEC) (54,55). These 
guidelines are considered here for the treatment of the tumours with conventional 
fractionation schedules with respect to volume and dose to a particular organ and their 
expected toxicity (Table 5-1). 
Table 5-1 Normal tissue toxicity profile of as per QUANTEC guidelines 
Normal tissue toxicity profile of as per QUANTEC guidelines 
Critical 
Structure 
Volume Dose/Volume 
Max 
Dose 
Toxicity 
Rate 
Toxicity 
Endpoint 
Brain stem 
The entire brain stem can be 
treated upto 54Gy 
<54 Gy <5% 
Neuropathy or 
necrosis 
Brain stem D1-10 cc ≤59 Gy 
 
<5% 
Neuropathy or 
necrosis 
Brain stem 
 
Maximum point 
dose 
<64 Gy <5% 
Neuropathy or 
necrosis 
Optic 
nerve/chiasm  
Maximum point 
dose 
<55 Gy <3% 
Optic 
neuropathy 
Optic 
nerve/chiasm  
Maximum point 
dose 
55-60 
Gy 
3-7% 
Optic 
neuropathy 
Optic 
nerve/chiasm  
Maximum point 
dose 
>60 Gy >7-20% 
Optic 
neuropathy 
Brain 
To partial 
brain  
<60 Gy <3% 
Symptomatic 
necrosis 
Brain 
To partial 
brain  
72 Gy 5% 
Symptomatic 
necrosis 
Brain 
To partial 
brain  
90 Gy 10% 
Symptomatic 
necrosis 
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5.12 Pituitary adenoma 
Pituitary adenomas are tumours that occur in the pituitary gland. Based on pathology, 
pituitary adenomas are divided into three categories, benign adenoma, atypical 
adenoma (invasive adenoma) and carcinomas.  Pituitary carcinomas accounts for 0.1% 
to 0.2%, whereas invasive adenomas accounts for approximately 35% remaining 
being benign adenomas (56).   
5.12.1 Epidemiology 
Tumors of the pituitary gland and sellar region represent approximately 10-15% of all 
brain tumors, of which the great majority in this region are pituitary adenomas (11).  
Majority of the pituitary tumours are undiagnosed and are often found at autopsy. 
The incidence of macroadenomas is similar in males and females. Symptomatic 
prolactinomas and Cushing disease are found more frequently in women.  Most 
pituitary tumors seen in young adults, but they may be seen in adolescents and elderly 
persons.  Acromegaly usually is seen in the fourth and fifth decades of life. 
In a population based study in England of a single community the prevalence of the 
pituitary adenomas per 100,000 was as follows (11). 
All adenomas     77.6 
Lactotroph adenomas     44.4 
Non-functioning adenomas    22.2 
32 
 
Somatotroph adenomas    8.6 
Corticotroph adenomas    1.2 
5.12.2 Anatomy 
Pituitary gland (Fig 7,8) is a midline structure, measures about 15mm in antero-
posterior and 12mm in craniocaudal axis.  Pituitary gland is located in the sella turcica 
(hypophysial fossa) which is a part of the sphenoid bone.  Pituitary gland is related 
superiorly to optic chiasm; inferiorly to inter cavernous venous sinus & sphenoid air 
sinus. Transsphenoidal approach through nose is a surgical technique performed to 
resect the tumour through sphenoid air cells. 
 
Fig 1: Anatomy of the pituitary gland 
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5.12.3 Clinical presentation 
Pituitary adenomas can present with symptoms of hormonal abnormalities or of local 
tumour growth leading to pressure effects. A pituitary adenoma may also present 
with non-specific headache, visual field defects, because of the pressure effects of the 
tumour. The most common field defects are classically bitemporal hemianopia and 
superior temporal quadrantanopia (57). 
 
Fig 2; MRI image showing Pituitary adenomas, a. Coronal view, b. Sagittal view 
 
5.12.4 Management 
5.12.4.1 Overview: 
Pituitary adenoma should be managed with multidisciplinary team including 
disciplines of neuroradiology, endocrinology, neurosurgery, radiation oncology and 
pathology. The goal of the treatment of Pituitary adenomas includes the assessment of 
accurate tumour extent, correction of the hormonal abnormalities; relieve pressure 
effects while minimising the injury to the surrounding normal structures (58). 
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Observation is an option for non-secreting microadenomas and small asymptomatic 
prolactinomas. If asymptomatic microadenomas are not treated, these patients can be 
observed with annual imaging studies. 
5.12.4.2 Medical management 
Medical management is mainstay of treatment in Prolactinomas and its role has been 
established in controlling the hormonal hypersecretion even in other secreting 
adenomas. Initially most Prolactinomas are managed with Dopamine agonists such as 
Bromocriptine, Pergolide or Lysuride. Medical intervention may reduce the size of the 
tumour and decrease the function. (58)A Somatostatin analogue, Octreotide is used as 
adjunctive therapy for medical management of pituitary growth hormone secreting 
adenomas(59). Growth hormone receptor antagonist Bromocriptine has also been 
widely used in treating Acromegaly(60). Newer growth hormone receptor antagonist 
Pegvisomant is also used for long term hormonal control (61). 
5.12.4.3 Surgical management 
The standard surgical approach for most of the pituitary adenomas is transsphenoidal 
microsurgery(62), which accounts for more than 95% of the procedures and rarely 
craniotomy is performed. This approach is safe and normalises the hormonal levels 
and relieves the pressure symptoms. 
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5.12.4.4 Radiation therapy 
Radiation therapy of pituitary adenoma is highly effective. It is recommended after 
subtotal resection of primary tumors such as macroadenomas, after gross total 
resection of endocrine active adenomas with postsurgical hormone secretion and for 
recurrent tumors.  Radiation therapy is also choice of treatment in patients who cannot 
undergo surgery due to co morbidities (63). 
Radiation is delivered using a total dose of around 45Gy or 5040cGy in 1.8Gy daily 
dose fractionation(15). Normalisation of the hormonal levels can take months to years 
after radiation therapy(16). Radiation therapy is effective in controlling the tumour 
growth in as high as 90-100% in many series regardless of the type of adenoma and 
technique of radiation used. The toxicities related to the radiation are generally low 
(15). 
5.12.4.5 The choice of radiation therapy 
The choice of radiation therapy to pituitary adenomas depends on the availability of 
the particular technique of radiation, physician preferences and perceived differences 
associated with each technique rather than the differences in clinical outcomes. The 
various modalities of delivering radiation include two dimensional external beam 
radiation therapy, conformal radiation therapy (3DCRT), fractionated stereotactic 
radiotherapy and proton beam radiation therapy. 
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5.12.4.6 Stereotactic radiotherapy 
In the past, Pituitary adenoma was treated with conventional radiotherapy(64). 
Because of the proximity of the organs at risk like, optic nerves, chiasm and brain 
stem, SRT is the preferred radiotherapy technique. Though impressive outcomes with  
stereotactic radiosurgery(SRS) using Gamma Knife have been reported by many(64) it 
may not be suitable to deliver high single fraction radiation for tumours that are large 
and tumours that are very close(<3-5mm) to optic pathways as dose limitation to optic 
apparatus is 8-10Gy in single fraction(50,51,65) Whereas stereotactic radiation with 
multiple fractions of standard dose per fraction allows sensitive surrounding normal 
structures to repair and regenerate during the course of radiation.  This has benefit of a 
radiobiologial advantage over the radiosurgery, especially for the structures like optic 
apparatus, which has a low α/β ratio (≤3 Gy) (21).  More recently many reports 
indicated promising outcomes with SRT(16). 
5.13 Craniopharyngioma 
The incidence of newly diagnosed craniopharyngiomas ranges from 0.13 to 2 per 
100,000 population per year (66). Presentation is equal in both sexes with bimodal age 
distribution. In children the peak incidence is around of 5-14 years where as in adults’ 
common age at presentation is in the age range of 65-74 years. Craniopharyngiomas 
accounts for 5% of all tumours in children and 50% of all sellar/para sellar tumours 
(66). 
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Craniopharyngioma is located in the suprasellar region and anatomically these 
tumours are in close proximity with the optic apparatus and brain stem. 
Craniopharyngiomas are histologically benign tumours.   Craniopharyngioma arises 
from epithelial remnants of the Rathke pouch in the suprasellar region(67). 
Craniopharyngioma is diagnosed mainly by clinical (neurological and endocrine 
symptoms) and radiological (Fig 9) (a calcified solid/cystic mass) findings. The 
diagnosis is confirmed by characteristic histological findings, of numerous microcysts. 
Tumour may also be associated with hyalinised calcified structures, foreign body giant 
cells and occasionally clefts having cholesterol granules. Craniopharyngioma may 
present with hormonal abnormalities due to compression of the pituitary or 
hypothalamus.  Lesion in the pre chiasmal area may compress the optic pathway, 
leading to visual field defects or decreased visual acuity, whereas retro chiasmal 
lesions may grow in to the third ventricle causing hydrocephalus or compression of 
the optic tracts. 
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Fig 3: MRI imaging of a patient diagnosed with Craniopharyngioma, from 
clockwise, T1W Post gado coronal, T1W sagittal and T2W transverse images 
on the lower side 
 
 
Management options of Cranipharyngioma include complete resection or subtotal 
resection followed by observation. External beam radiation therapy is indicated for 
recurrent disease or subtotal resection of the tumour 
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Stereotactic radiotherapy (SRT) is considered as the technique of choice for radiation 
in these patients because it allows the precise delivery of high-dose radiation to the 
tumour, while minimizing irradiation of surrounding critical structures (68). Daniela 
and Ertner et al., in a retrospective series have reported that, SRT using a Linear 
accelerator in Craniopharyngioma is safe and toxicity is extremely low. Visual acuity 
was improved in 5/12 patients and there was no new visual impairment during the 
follow up post SRT. After SRT only one out of 12 patients developed 
panhypopituitarism while 6/12 developed partial hypopituitarism (68). 
Stephanie E. Combs, et al., reported excellent long-term outcome for 
Craniopharyngiomas with regard to local control as well as treatment-related side 
effects using linear accelerator based SRT (69). 
5.14 Radiation induced Second cancer and Cognitive functions 
Risk of secondary cancer information comes from general population comes from 
Atomic bomb survivors and patients who are treated with radiotherapy. Studies on 
survivors of atomic bomb have shown that the risk increases linearly up to 2Sv. Risk 
of radiation induced cancers for several organs increases substantially at doses far 
above 2Gy(70). Though the incidence of cancer risk may be low but its a very serious 
and potentially fatal late complication of radiation. In a retrospective study by Nishio 
et al., (71) 11 patients who received therapeutic cranial irradiation with dose range of 
24-110Gy (is this dose range correct) (median of 54 Gy) to their primary disease 
developed secondary tumours within the span of 13 years. All the tumours were in the 
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field of previous radiation and satisfied with definitions of Radiation induced 
neoplasms. Patients tend to be young (1.3-42 years; median age of 22 years) and the 
median latency period was 14.5 years. 
Erridge et al., (13) in an audit on patients with pituitary adenoma treated with 
radiotherapy reported a good long term control of tumour with increased risk for intra-
cranial tumours with radiation. The 20-year actuarial risk 1.9% (CI 0–2.6%), and a 
relative risk of 5.65 (0.53–20.77, p = 0.10) of men and 9.94 (0.94–36.56, p = 0.04) 
women observed.  Risk of secondary brain tumour risk was 1.9% at 20 years in a 
study by Michel Brada on pituitary tumours (72). 
Neglia et al., (73) et al have studied incidence of occurrence of subsequent primary 
central nervous system (CNS) tumours as a late event in children treated for leukemia 
or brain tumours on 14361 patients. Subsequent CNS primary neoplasms were 
diagnosed in 116 individuals. Gliomas (n=40) occurred after a median of 9 years and 
meningiomas (n=66), after a median of 17 years.  The dose response for the excess 
relative risk was linear for both meningiomas and gliomas. Highest risk was found in 
children exposed less than 5 years of age. Radiation dose response relationship was 
highly statistically significant (P<0.001) for all CNS tumors. Odds ratios for glioma 
rose sharply across the radiation categories and it was highest (21-fold) for doses of 
30-44.9Gy.  Highest risk of radiation induced secondary cancers was found in patients 
who received more doses, who survived longer and at young age. 
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Reimers et al., (74) described association between cognitive outcomes in survivors of 
the 133 childhood CNS tumours.  The mean intelligence (IQ) scores were 
substantially lower than the expected means of the general population, the patients 
treated with RT found to be significantly affected. Radiation therapy was found to be 
most important risk factor for the impaired cognitive functions. The mean observed 
full scale IQ was 97.1 (SD = 14.3) for the non-irradiated patients and 78.8 (SD = 14.3) 
for the irradiated patients (P < 0.001). 
In a study by Guinan et al., (75) on cognitive effect of the  pituitary tumours and their 
treatment on cognitive effects, have shown memory was more severely affected in 
patients who had received adjuvant radiation. 
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6 METHODOLGY 
6.1 Setting 
The planning CT image sets of patients who had undergone stereotactic radiotherapy 
(SRT) for pituitary adenoma or craniopharyngiomas were used in this study.  Twenty 
such patient data sets were available in the iPlan brain lab data system from April 
2014 to August 2015. These data sets were included in our study. CT image sets were 
used to generate three separate plans with three separate techniques (SCF, SCA and 
DCA respectively) and these plans were compared across for various parameters as 
mentioned below. 
6.2 Participants 
The study was carried out on image sets acquired on patients with Craniopharyngioma 
and Pituitary adenoma and who had received SRT. The SCF plans were already 
generated for treatment using Brain LAB, iPlan RT V.4.5.3 Germany, Treatment 
Planning System (TPS) software and treated with Clinac-DMX 2100-CD linear 
accelerator Varian, Palo Alto, CA. 
6.3 Inclusion criteria 
The patients with biopsy proven diagnosis of either Craniopharyngioma or Pituitary 
adenoma who have been treated with SRT in department of radiotherapy unit 1 from 
April 2014 to August 2015 were selected for the study. Fractionated SRT was 
performed using a Clinac-DMX 2100-CD linear accelerator Varian, Palo Alto, CA. 
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The plans were initially generated under Brain LAB, iPlan RT V.4.5.3 Germany; 
Treatment Planning System (TPS)   were selected. 
6.4 Exclusion criteria: 
Image sets of the patients with other histologies. 
6.5 Sample size: 
Since the study being pilot study, the sample size was chosen to be 20. 
6.6 Source: 
Department register having the details of the patients who were treated with SRT were 
searched from April 2014 to August 2015.  Image sets of patients with Pituitary 
adenoma and Craniopharyngiomas treated with linear accelerator based SRT 
techniques were selected. The image sets were available in Brain LAB, iPlan RT 
V.4.5.3 Germany, Treatment Planning System (TPS). 
6.7 Selection Method: 
The images sets of 20 consecutive patients treated for Pituitary adenoma or 
Craniopharyngioma were taken for the study retrospectively and prospectively.  The 
patient selection involves the search of the patients who have been treated in the 
during the period April 2014 to August 2015 who were treated under Unit I of 
radiotherapy department, Christian medical college, Vellore, Tamil Nadu, India. All 
the patients underwent the process of planning CT using GTC frame and a BRW 
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localiser system.  All the patients in the eligible population source were selected and 
assigned a unique identification number. 
6.8 Consent 
This study is a type of observational study performed on the image sets of patients 
diagnosed to have Pituitary adenoma and Craniopharyngioma. This data containing 
CT image was available in the Brain LAB, iPlan RT V.4.5.3 Germany, Treatment 
Planning System (TPS) archives and conformed to the patient confidentiality and 
norms for the electronic data.  So the consent waiver was applied for and this was 
accepted by our Institutional Review Board scientific and ethics committee. 
6.9 List of materials used for this study: 
The following were used to perform this study, Treatment planning system: 
 Treatment planning system 
 Patient’s image data sets 
 Linear accelerator 
 Phantom 
6.9.1.1 Treatment planning system 
In our department we have VARIAN MEDICAL SYSTEMS, Inc, CLINAC (Linear 
accelerator) and Brain LAB, iPlan RT V.4.5.3 Germany, Treatment Planning System 
(TPS) which is regularly used for the treatment of the patients for stereotactic 
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radiotherapy. The same software was used for the image registration, localisation, 
delineation of the tumours and organs at risk. The beam placement, plan generation, 
calculation of the dose, generation of the dose volume histograms were done after the 
delineation of the structures. CLINAC the Linear Accelerator, used regularly for the 
treatment of these patients, was used to analyse the efficacy of the plans on a 
phantom. 
The study utilised the Brain LAB, iPlan RT V.4.5.3 Germany, Treatment Planning 
System (TPS) configured with dose calculation and treatment delivery algorithms of 
Varian CLINAC(TM) 6 MV (Megavoltage) photon beam, the Radionics Brown 
Robert Wells stereotactic frame and Brain lab m3 micro multileaf collimator. 
6.9.1.2 Patient’s data image data sets 
The image sets are the planning CT scan images of the patients performed during the 
time of SRT treatment. These data sets were available in the TPS and same image sets 
are used for the delineation of GTV and normal organs and planning purposes. 
6.9.1.3 Linear Accelerator 
Linear accelerator is megavoltage x-ray generator by accelerating the charged 
particles. Clinac-DMX 2100-CD linear accelerator Varian, Palo Alto, CA is available 
in our department for the purpose of treatment of the patients. Same machine is used 
here to assess the plans. 
47 
 
6.9.1.4 Phantom 
Phantom is a models of human body used in dosimetric studies of the ionising 
radiation. We use water phantom in this study to measure the time required to deliver 
the prescribed radiation for one patients plan. 
6.10 Contouring 
Patient’s planning computed tomography datasets, with 3-mm-slice thickness from 
vertex to lower border of second cervical vertebra was retrieved from the Brain LAB, 
iPlan RT V.4.5.3 Germany, Treatment Planning System (TPS) for computation of 
treatment plans. The image data sets of patients with pituitary adenoma and 
craniopharyngioma who underwent planning CT simulation with Gill Thomas 
Cosman stereotactic localizing frame along with BRW localiser system form April 
2014 to August 2015 were selected for contouring. The same image data sets were 
used for all the three treatment techniques. 
The gross tumour volume (GTV) was contoured by the Neurosurgeon for all these 
patients at the time of initial planning for SRT. The GTV was outlined on axial CT 
fused with axial T1 Gadolinium magnetic resonance images. The planning target 
volume was given by a radiation oncologist by expanding the GTV by 3 mm in all 
directions. The Organs at risk (OAR) were contoured by the radiation oncologist or 
Neurosurgeon. 
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6.11 Method of generating the SRT plans. 
Each patient will have three plans using the same PTV and OARs; SCF, SCA and 
DCA. For ease of dosimetric analysis, we prescribed a uniform dose (54Gy in 30 
fractions) to all planning target volumes (PTV) irrespective of the diagnosis. 
Treatment planning system (TPS) Brain LAB, iPlan RT version 4.5.3 uses the pencil 
beam algorithm with tissue inhomogeneity correction to calculate the dose 
distribution. The grid size for calculation was 2-mm pixel. The same dose 
requirements for PTV (minimum of 95%) coverage and OAR sparing were set for all 
the three techniques. All the treatment planning was done by one physicist with a 
supervision of the senior physicist to minimize interoperator variations.  Moreover, all 
plans were veriﬁed by radiation oncologist to ensure that the quality of each plan met 
the required standard. 
The treatment plan was performed by the medical physicist using the same PTV for all 
the plans. All the plans were performed under Brain LAB, iPlan RT V.4.5.3 Germany, 
Treatment Planning System (TPS) software. 
For SCF plan single isocenter with 3 to 7 noncoplanar beams were used. Beam 
shaping was tailored by the brainlab 3mm micro MLCs.  The static conformal beam 
technique uses non-coplanar uniform static fields, defined by the beam's eye view 
projections of the target volume, and directed to a single isocenter. To produce these 
plans, the treatment isocenter was first placed at the geometric centre of the target. 
Then, the beams were entered in various directions so as to minimize the overlap 
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between the entrance and exit beam paths.  A margin of around 3mm was added to 
each beam in order to have approximately the 95% (of the maximum dose) isodose 
surface completely encompassing the target volume. The collimator angle was always 
optimized in order to irradiate the smallest possible area for each beam. 
Static conformal arc was planned with 3-6 arcs in a non coplanar fashion with single 
isocentre. The dynamic conformal arc was planned similarly as in the static arc 
technique, but in the case dynamic arc technique mMLCs fit to the shape of the 
beam’s eye view every 10 degree gantry movement from the starting angle till the 
end. 
6.12 Dosimetric Comparison of the three plans 
Dosimetric analysis was performed using DVHs and 2D dose displays, RTOG quality 
assurance guidelines of SRT like conformity index(CI), homogeneity index(HI) and 
quality of target coverage. Analysis of plans was also performed using parameters like 
maximum dose, minimum dose and mean dose to the target, dose received by OARs 
and the volume of brain receiving 5Gy, 6Gy, 10Gy, 20Gy and 40Gy. 
6.12.1 Conformity index: 
The RTOG “Conformity index” analyses the conformity based on the formula, 
Conformity Index (RTOG) =  
Where VRI reference isodose volume and TV is target volume. 
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The RTOG conformity index 1 is an ideal form of conformation, where the reference 
isodose volume is exactly same as target volume.   A conformity index greater than 1 
indicates that the reference isodose volume is greater than the target volume; this 
represents irradiated volume is greater than the target volume and includes healthy 
tissues surrounding the target. If the conformity index is less than 1, the target volume 
is only partially covered by reference isodose or irradiated.  It may be difficult to get 
conformity index of 1 in practical situations and rarely achieved, so RTOG guidelines, 
defined ranges of conformity index values to determine the quality of conformation. If 
the conformity index is between 1 and 2, treatment is considered to comply with the 
treatment plan; an index between 2 and 2.5, or 0.9 and 1, is considered to be a minor 
violation of the protocol, and an index less than 0.9 or more than 2.5 is considered to 
be a major violation of the protocol. 
6.12.2 Homogeneity index: 
The concept of homogeneity index (HI) was developed to analyse the spatial dose 
distribution in each section of the treatment plan.  HI was described as per the RTOG, 
HIRTOG = , where, 
Imax = maximum dose received by the target, and RI = reference isodose (95% 
isodose).  If the HI was ≤2, treatment was considered to comply with the protocol, if 
this index was between 2 to 2.5, it was considered as minor violation, but if the index 
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exceeded 2.5, the violation of the protocol was considered to be major, but might 
nevertheless considered acceptable(90). 
6.12.3 Quality of coverage 
Quality of coverage was calculated using formula as described in the RTOG, 
Quality of coverage (RTOG)  I min/RI 
Where I-min is minimum dose received by the PTV and RI is the reference isodose 
(reference isodose was taken as 95% of the prescribed dose). 
For the quality coverage as in formula 1, if the minimum dose received by the PTV is 
90 % of the prescribed dose, the treatment plan is considered to be complying with 
protocol. If the minimum dose received by the target is between 80 to 89% of the 
prescribed dose, the protocol is considered to be minor violation.  If the minimum 
dose received by the target is less than 80 % of the prescribed dose, it is considered to 
be major protocol violation. 
6.12.4 Organs at risk 
For the OARs, maximum dose was compared across three plans. 
The volume of brain receiving 5Gy, 6Gy, 10Gy, 20Gy and 40Gy was compared across 
three plans for all the patient data sets. This helped us in selection of a better SRT 
technique with regard to spillage of lower dose. 
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6.12.5 Treatment Time  
We estimated the time taken for to deliver the intended radiation dose for all the three 
plans for 2 patient data sets. The time taken for positioning of the patient for the 
treatment, frame fitting and adjustment were considered to be constant for all the three 
plans. However the time taken to deliver radiation, isocentre matching with room 
lasers, number of monitor units may differ. So treatment plans are analysed in terms of 
time taken to deliver each fraction of RT and initial time taken for verification 
purpose. 
6.13 Statistical analysis: 
  
Data entry was done in Epidata version 3.1 and was analysed using SPSS 17.0 
(Statistical Package for social sciences). For continuous data, the descriptive statistics 
such as n, mean, standard deviation, median, minimum and maximum was 
represented. For categorical data, the number of patient data sets and percentage was 
presented. 
Based on the normality of the data the parametric ANOVA test or non parametric 
Kruskal Wallis test was used to compare the three stereotactic radiotherapy treatment 
techniques. 
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6.14 Detailed diagrammatic Algorithm of the study 
 
 
 
 
 
 
 
 
 
 
 
 
Data Collection/ Patients treated with SRT from April 2014 till August 
2015 
Delineation of the target volumes and Organs at risk (contouring) 
Develop three SRT plans (SCF, SCA and DCA) for all the patients image 
sets, using software iPlan RT4.5.3, Brain LAB, Germany 
Statistical analysis of the data 
 
 Phantom study 
Analysis and interpretation of the results 
Data collection using Epidata, software version 3.1 software. 
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7 RESULTS 
7.1 Patient Characteristics 
Patients’ age ranged from 6 to 77 years with the median age of 33 years. Twelve 
patients were diagnosed to have Pituitary adenoma and 8 with Craniopharyngioma.  
For dosimetry purposes the dose prescribed was 5400cGy in 30 fractions in all the 
plans for all data sets. The characteristics of the patients are listed in the Table 7.1 
Table-7-1Patient Characteristics 
Serial No Age in years Gender Diagnosis PTV Vol. in cc 
1 33 Female Pituitary adenoma 11.24 
2 55 Male Pituitary adenoma 12.91 
3 16 Female Craniopharyngioma 06.47 
4 11 Female Craniopharyngioma 12.66 
5 36 Male Pituitary adenoma 07.62 
6 13 Male Pituitary adenoma 14.45 
7 48 Female Craniopharyngioma 13.67 
8 13 Female Craniopharyngioma 15.13 
9 38 Male Pituitary adenoma 14.38 
10 75 Female Pituitary adenoma 25.06 
11 33 Female Pituitary adenoma 16.32 
12 77 Male Pituitary adenoma 11.45 
13 47 Male Pituitary adenoma 41.61 
14 6 Male Craniopharyngioma 23.94 
15 28 Female Pituitary adenoma 22.02 
16 7 Female Craniopharyngioma 49.15 
17 39 Female Pituitary adenoma 14.51 
18 67 Male Pituitary adenoma 11.79 
19 32 Female Craniopharyngioma 23.49 
20 6 Male Craniopharyngioma 34.28 
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7.2  Planning Target Volume 
The planning target volume ranged from 6.47cc to 49.15cc, with a median PTV of 
14.48cc. Fig. 10 represents the volume of PTV in all the patients. Thirteen patients 
had PTV <20cc and 7 had >20cc volume. 
 
Fig 4: PTV volumes for 20 patient data sets 
 
7.3 Reference Isodose Volume 
Reference isodose volume was taken as the volume covered by 95% isodose line. The 
volume of the 95% isodose was generated and volume was measured in cc. 
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Table 7-2 Planning Target Volume and corresponding Reference Isodose 
Volumes of three SRT techniques 
 
Reference Isodose Volume 
S no Volume of PTV SCF SCA DCA 
1 11.24 17.06 14.52 16.69 
2 12.91 15.35 16.39 17.86 
3 6.47 9.43 9.21 8.93 
4 12.66 20.65 18.78 21.67 
5 7.62 10.76 10.38 10.52 
6 14.45 19.02 19.75 20.59 
7 13.67 20.16 16.18 17.16 
8 15.13 16.54 22.01 21.96 
9 14.38 17.06 17.56 17.19 
10 25.06 29.40 34.63 32.23 
11 16.32 20.63 20.99 20.84 
12 11.45 13.78 15.61 13.36 
13 41.61 66.65 57.30 50.72 
14 23.94 26.68 30.12 28.70 
15 22.02 34.43 32.62 27.20 
16 49.15 60.59 68.62 63.84 
17 14.51 19.18 19.43 17.83 
18 11.79 20.72 20.65 20.60 
19 23.49 26.96 27.96 29.36 
20 34.28 42.23 39.9 42.86 
Mean + SD 19.11 ± 11.21 25.36 ± 15.25 25.63 ± 15.14 25.01 ± 13.67 
p Value 0.062 
SCF=Static Conformal Field, SCA=Static Conformal Arc and DCA=Dynamic 
Conformal Arc 
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Average volume of the reference isodose was around 25cc in all the three plans 
however there was a minimal reduction in this volume in the DCA compared to SCF 
and SCA plans. The values are presented in Table 7.2 and Fig 11. 
 
Fig 5: Reference Isodose Volume with respect to the PTV in all the subjects 
(PTV= Planning target volume, RIV= Reference isodose volume) 
 
To assess the correlation between Reference Isodose Volume and   PTV, spearman 
rank correlation (rho) was used. The PTV and RIV  value in the techniques SCF, SCA 
and DCA were positively correlated with rho of 0.84, 0.95 and 0.92 respectively, 
which is statistically significant with p-value of <0.001( Fig 12). 
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Fig 6: Correlation of Reference Isodose volumes with PTV 
 
7.4 PTV receiving 95% of the prescribed dose 
Mean PTV receiving the 95% of the prescription dose was reported in all the three 
plans. PTV coverage was adequate for SCF and DCA plans but <95% was covered in 
SCA plans, however the difference was not statistically significant (p=0.206). One 
plan in SCF and two plans in SCA were covered with <90% of the prescribed dose as 
depicted in Table 7.3 and Fig 13. 
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Table 7-3 PTV receiving 95% Dose 
 
PTV receiving 95% isodose 
S No SCF SCA DCA 
1 96.00 96.90 97.90 
2 98.80 97.60 99.00 
3 96.00 96.50 94.00 
4 95.50 91.00 99.20 
5 95.56 96.20 92.40 
6 94.70 93.90 96.00 
7 99.70 89.50 93.00 
8 94.50 96.90 97.50 
9 97.15 96.70 95.18 
10 94.60 94.80 93.30 
11 95.70 92.70 91.90 
12 90.00 97.20 96.60 
13 95.40 96.60 96.80 
14 89.60 95.40 95.50 
15 95.90 95.00 98.10 
16 95.40 88.00 95.40 
17 97.60 95.70 98.60 
18 96.00 93.40 91.80 
19 95.30 90.00 94.50 
20 94.50 91.70 95.80 
Mean & SD 95.39 ± 2.35 94.29 ± 2.89 95.62 ± 2.36 
p Value 0.206 
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Fig 7: Mean PTV receiving the 95% isodose in the three SRT plans 
 
7.5 Conformity index 
The conformity index was developed to analyse the spatial dose distribution in each 
section of the target.  RTOG defined conformity index as with the formula, 
Conformity Index (RTOG) =    where VRI reference isodose volume, and TV 
target volume. Conformity index was calculated for all the three plans for patient data 
sets. 
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Table 7-4 Conformity Index of the three SRT plans 
 
Conformity Index 
S No SCF SCA DCA 
1 1.52 1.29 1.48 
2 1.19 1.27 1.38 
3 1.46 1.42 1.38 
4 1.63 1.48 1.71 
5 1.41 1.36 1.38 
6 1.32 1.37 1.42 
7 1.47 1.18 1.26 
8 1.09 1.45 1.45 
9 1.19 1.22 1.20 
10 1.17 1.38 1.29 
11 1.26 1.29 1.28 
12 1.20 1.36 1.17 
13 1.60 1.38 1.22 
14 1.11 1.26 1.20 
15 1.56 1.48 1.24 
16 1.23 1.40 1.30 
17 1.32 1.34 1.23 
18 1.76 1.75 1.75 
19 1.15 1.19 1.25 
20 1.23 1.16 1.25 
Average & SD 1.34 ± 0.19 1.35 ± 0.13 1.34 ± 0.16 
p Value 0.951 
SCF =Static conformal field, SCA=Static conformal arc, DCA=Dynamic conformal 
arc, SD=Standard deviation 
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RTOG conformity index was within acceptable limits (Conformity Index between 1 
and 2) for all the techniques across all patient data sets. Mean conformity for SCF, 
SCA and DCA was 1.34, 1.35 and 1.34 respectively. The difference in the conformity 
indices among the three plans was not significant (p value = 0.951).  In SCF plan 75% 
of the plans were having Conformity index of <1.5, whereas in the case of SCA and 
DCA plans 95% and 90% had Conformity Index of <1.5 (Table 7.4 and Fig. 14). 
 
 
Fig 8: Conformity Index of 20 patient data sets for the three SRT plans 
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7.6 Homogeneity index 
The homogeneity index represents how the dose is spatially distributed in the target 
volume.   HI was described by the RTOG as, HIRTOG =     
Imax = maximum isodose in the target, and RI = reference isodose. 
Table 7-5 Homogeneity index showing mean and standard deviation in three 
SRT plans 
Homogeneity index 
S No SCF SCA DCA 
1 1.07 1.07 1.07 
2 1.06 1.07 1.07 
3 1.08 1.06 1.06 
4 1.06 1.03 1.08 
5 1.06 1.09 1.08 
6 1.06 1.09 1.07 
7 1.06 1.08 1.07 
8 1.07 1.07 1.06 
9 1.06 1.08 1.08 
10 1.07 1.09 1.08 
11 1.07 1.08 1.07 
12 1.07 1.05 1.07 
13 1.07 1.07 1.08 
14 1.08 1.08 1.07 
15 1.06 1.07 1.06 
16 1.06 1.11 1.08 
17 1.06 1.10 1.08 
18 1.08 1.08 1.11 
19 1.08 1.10 1.09 
20 1.08 1.12 1.08 
Average & 
SD 
1.07 ± 0.01 1.08 ± .02 1.08 ± .01 
p Value 0.033 
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SCF =Static conformal field, SCA=Static conformal arc, DCA=Dynamic conformal 
arc, SD=Standard deviation 
The volume of the Reference Isodose (95% isodose line) was created and measured in 
cc. Mean homogeneity index was 1.07 ± 0.01, to 1.08 ± 0.02 and 1.08 ± 0.02 in SCF, 
SCA and DCA plans respectively (p value=0.033).  In all the plans the homogeneity 
index was within the RTOG protocol. The minimum homogeneity index was 1.03 and 
maximum homogeneity was 1.12 across all the plans. In majority of the plans the 
homogeneity index was <1.10, however four out of 20 plans in SCA and one out of 20 
plans in DCA was above 1.10. Homogeneity index is presented in Table 7.5 and Fig 
15. 
 
Fig 9: Homogeneity Indices of all the three plans 
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7.7 Quality of Coverage 
Quality of coverage (RTOG)    where I-min is minimum dose received by the 
target and RI is the reference isodose. 
Table 7-6 Quality of coverage for all the data sets for three-SRT plans  
Quality of Coverage 
S No SCF SCA DCA 
1 95.05 89.89 96.11 
2 96.00 91.37 96.42 
3 94.84 86.00 95.58 
4 85.05 79.89 96.95 
5 96.84 79.26 103.78 
6 94.21 86.21 95.47 
7 95.47 89.79 96.22 
8 90.00 90.53 94.21 
9 94.84 90.53 94.42 
10 92.63 88.74 90.40 
11 91.68 92.42 91.37 
12 94.83 95.89 92.32 
13 86.84 90.32 92.53 
14 83.26 92.95 92.74 
15 95.37 79.89 91.27 
16 93.16 78.95 89.58 
17 97.05 78.53 96.63 
18 85.68 89.26 80.32 
19 92.74 82.95 93.37 
20 81.76 60.18 89.58 
Average & SD 91.87 ± 4.7 85.68 ± 8.02 93.46 ±4.51 
p Value 0.001 
 
SCF =Static conformal field, SCA=Static conformal arc, DCA=Dynamic conformal 
arc, SD=Standard deviation 
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Mean Quality of coverage was within the acceptable limits of RTOG (>90%) in SCF 
and DCA plans, but for SCA plan quality of coverage had minor deviation (80-89%).  
The mean quality of coverage was 85.68 ± 8.02 % in SCA plan however it was within 
the acceptable limit with minor deviation (Fig 4.7). This difference of quality of 
coverage among the three plans was statistically significant (p <0.001). The quality of 
coverage showed minor deviation for 5 SCF plans, 7 SCA plans and 3 DCA plans. 
There was major deviation in 6 SCA plans and no major deviation in SCF and DCA 
plans (Table 7.6 and Fig 16). 
 
Fig 10: Mean Quality of target Coverage of the three SRT plans 
SCF =Static conformal field, SCA=Static conformal arc, DCA=Dynamic conformal 
arc 
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68 
 
 
Fig 11: of coverage in percentage for three SRT techniques 
 
The association between PTV and Quality of Coverage from the plans SCF, SCA and 
DCA were negatively correlated with the spearman rank correlation of -0.46, -0.14 
and -0.58 respectively (Fig 18). The Quality of Coverage from technique SCF and 
technique SCA was statistically significant with the p-value of 0.041 and 0.007 
respectively. 
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Fig 12: Correlation of the Quality of coverage with volume of PTV 
Table 7-7 p values of the three SRT techniques for Conformity Index, 
Homogeneity Index and Quality of coverage 
 
P values 
Plans 
Conformity 
Index 
Homogeneity Index Quality of Coverage 
SCA vs 
SCF 
0.813 0.008 0.001 
DCA vs 
SCF 
0.965 0.075 0.357 
DCA vs 
SCA 
0.779 0.335 0.001 
 
When SCF technique was compared with SCA there was significant statistical 
difference for the Homogeniety index and Quality of Coverage but not for Conformity 
Index.  There was no statistical significant difference between DCA and SCF plans for 
Conformity Index, Homogeniety Index and Quality of Coverage  parameters/ 
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variables. Comparison between DCA and SCA revealed a statistical difference for 
Quality of Coverage (Mean quality of coverage was 93.46% in DCA plan and 85.68% 
in SCA) but not for Conformity and Homogeniety indices (Table 7.7). 
7.8 Maximum, Minimum and Mean dose in the PTV 
The mean maximum dose in the SCF plan was 101.57 ± 0.262, whereas in SCA and 
DCA plans, the mean maximum dose was higher but it was not statistically 
significant. The mean minimum dose in the target was lowest in the SCA plan (81.39 
± 4.11) as compared to the SCF and DCA plans which was statistically significant 
(p=0.002). The average mean dose was about 98% in all the three plans (Table 7.8). 
Table 7-8 the average maximum, minimum and mean dose of the target 
 
Doses in the target in percentage 
Plan Measure Maximum dose Minimum Dose Mean Dose 
SCF Mean+SD 101.57 ± 0.26 87.27  ± 2.51 98.05 ± 0.26 
SCA Mean+SD 102.45 ± 1.10 81.39 ± 4.11 98.40±  0.35 
DCA Mean+SD 102.08 ± 0.34 88.78 ± 1.95 98.56 ± 0.28 
 
p-Value 0.319 0.002 0.22 
SCF =Static conformal field, SCA=Static conformal arc, DCA=Dynamic conformal 
arc 
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7.9 Monitor Units for the three SRT plans 
All the plans were compared in terms of time required to deliver single fraction.  The 
time for the set up of the patient for in all the three plans assumed to be same. 
However the difference in the time of treatment delivery may vary depending on the 
number of monitor units required to deliver the radiation. In this study, monitor units 
was calculated to deliver single fraction (1.8Gy) in SCF, SCA and DCA techniques 
for 10 patients’ treatment plans (Table 7.9). 
Table 7-9 Monitor Units required for delivering single fraction 
  
Monitor Units 
S No SCF SCA DCA 
1 251 251 249 
2 271 266 268 
3 283 262 262 
4 256 261 257 
5 264 278 279 
6 269 263 259 
7 271 267 268 
8 254 264 259 
9 274 266 268 
10 260 268 255 
Average & SD 265.3 ± 10 264.6 ± 6 262.4 ± 8 
p value 0.54 
SCF= Static conformal field, SCA=Static conformal arc, DCA=Dynamic conformal 
arc and SD= Standard deviation. 
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The average monitor units required to deliver the single fraction of radiation did not 
differ significantly in the three plans. However the monitor units to deliver single fraction 
of RT is relatively less in the DCA plans, but the difference was not statistically 
significant (p=0.54). Median values of monitor units were 266.5, 265 and 260.5 in SCF, 
SCA and DCA plans respectively.  
7.10 DVH Analysis  
The comparison of the isodose lines of one patient data set is shown in the Fig 19. In 
DCA and SCA plans, lower isodose lines are conformal to the target compared to the 
SCF plan. The isodose distribution analysis showed that in SCF plan the dose spillage 
was more on the temporal lobes. 
 
 
Fig 13 : distribution of one of the patient’s plans, left-SCF plan, middle- SCA and right -
DCA plan. Blue coloured isodose represents 30% isodose line 
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7.11 Dose to the organs at risk (OAR) 
7.11.1 Dose to Brain stem 
Table 7-10 dose to brain stem  
Dose to brain stem 
S No SCF SCA DCA 
1 52.34 53.05 52.92 
2 23.45 37.46 29.80 
3 51.71 50.68 50.92 
4 44.88 50.44 49.00 
5 46.98 45.57 48.03 
6 38.04 41.28 37.30 
7 53.61 53.66 53.74 
8 53.45 54.48 54.24 
9 49.06 50.85 48.50 
10 51.16 53.58 51.74 
11 53.76 53.31 53.49 
12 25.87 47.98 36.95 
13 54.39 53.53 54.09 
14 51.96 52.99 54.57 
15 52.69 54.56 53.13 
16 53.92 54.85 54.75 
17 53.61 56.82 53.59 
18 26.56 28.32 33.70 
19 53.93 52.70 52.49 
20 54.11 55.46 54.67 
Average 47.274 50.0785 48.881 
Std Dev ± 10.27 ±7.04 ±7.79 
p value 0.019 
 
The maximum point dose to brain stem ranged from 23.45Gy to 54.39Gy in SCF, 
28.32Gy to 56.82Gy in SCA and 29.8Gy to 54.75Gy in DCA plan. SCF technique 
delivered the minimum dose to the brain stem with 2 plans exceeding 54Gy while in 
SCA and DCA 5 each exceeded 54Gy.  Highest dose to brain stem, 56.82 Gy was 
found in one of the SCA plans (Table 7.10, Fig 20 and 21).  The average dose to brain 
stem was minimal in SCF plans and it was statistically significant (p= 0.019).  
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Fig 14: maximum point dose to brain stem of three SRT plans 
 
 
Fig 15: Radar diagram showing the maximum dose to the brain stem from 20Gy 
to 60Gy in three techniques of SRT for 20 patients’ data sets 
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7.11.2 Dose to Optic chiasm 
Most of the patient data sets had optic chiasm was inside the target volume or closely 
associated with target volume. 
Table 7-11 Maximum dose to the optic chiasm in the three SRT plans 
Dose to Optic chiasm 
S No SCF SCA DCA 
1 54.81 54.62 54.67 
2 53.35 54.40   54.88 
3 53.58 54.59 54.44 
4 53.25 53.16 53.06 
5 53.55 53.84 54.35 
6 54.38 54.94 54.56 
7 54.22 53.82 53.87 
8 53.61 54.88 54.50 
9 53.45 53.78 53.88 
10 53.57 55.50 54.60 
11 54.12 54.83 54.42 
12 54.53 54.56 54.57 
13 53.62 54.46 54.03 
14 54.00 54.46 52.71 
15 53.47 54.56 53.96 
16 52.99 54.61 53.96 
17 53.85 55.51   54.23 
18 54.37 54.83 55.69 
19 53.64 53.73 54.04 
20 53.10 54.96 54.18 
Average 53.77 54.50 54.23 
SD ± 0.49 ±0.59 ±0.62 
p value 0.001  
CF =Static conformal field, SCA=Static conformal arc, DCA=Dynamic conformal 
arc 
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The maximum point dose received by optic chiasm ranged from 52.99 to 54.81Gy in 
SCF, 53.16 to 55.51Gy in SCA and 52.59 to 55.69Gy in DCA plans. Static conformal 
field (SCF) plan delivered the least dose to optic chiasm compared to SCA and DCA 
plans. None of the plans exceeded 55Gy to optic chiasm in SCF plans, whereas two 
plans in SCA and one plan in DCA plan (Table 7.11, Fig 22 and 23).  The dmax 
exceeded > 54Gy in 7/20, 15/20 and 14/20 in SCF, SCA and DCA plans respectively. 
Dose to optic chiasm is represented in radar diagram in Fig 22. 
 
Fig 16: The maximum dose to the optic chiasm in three SRT plans 
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Fig 17: The radar diagram showing dose to the optic chiasm in 20 data sets for 
three SRT plans (SCF, SCA and DCA) 
 
7.11.3  Dose to Optic nerves 
The maximum dose to left optic nerve ranged from 2.96Gy to 51.77Gy, 7.15Gy to 
52.06Gy and 4.36Gy to 52.09Gy in SCF, SCA and DCA plans respectively. Mean 
doses with standard deviation are presented in Table 7.12 (p value= 0.559). The 
maximum doses to right optic nerve ranged from 5.72Gy to 51.35Gy, 8.88Gy to 
52.84Gy and 7.55Gy to 52.65Gy in SCF, SCA and DCA plans respectively. The mean 
values are presented in Table 7.12 with standard deviation (p=0.001). 
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Table 7-12  Maximum doses to the left and right optic nerves with mean, 
standard deviation and p values 
 
Dose to left optic nerve Dose to right optic nerve 
S No SCF SCA DCA SCF SCA DCA 
1 20.67 22.23 28.87 35.40 35.40 36.14 
2 17.37 23.69 22.67 14.98 23.05 20.44 
3 32.39 21.79 26.67 50.35 50.06 51.04 
4 19.42 23.22 26.49 7.05 28.46 24.42 
5 28.35 12.32 13.21 41.26 37.59 46.89 
6 51.77 52.06 52.49 51.35 52.84 52.65 
7 26.11 25.77 22.17 21.85 25.59 22.98 
8 2.96 7.15 4.36 9.22 22.10 23.62 
9 16.73 17.9 20.30 13.75 21.52 20.66 
10 49.86 49.7 51.00 49.59 51.98 52.69 
11 27.27 33.34 32.73 24.07 30.33 30.26 
12 36.90 40.42 34.14 26.10 36.00 27.96 
13 32.58 25.05 30.30 28.59 28.62 30.39 
14 31.00 32.57 33.18 44.03 45.77 46.32 
15 44.87 37.53 43.36 49.55 51.45 49.19 
16 49.90 40.86 47.62 50.42 47.63 50.82 
17 28.94 25.25 25.21 49.08 45.11 45.94 
18 15.33 31.75 29.17 19.02 23.65 23.96 
19 5.04 8.54 8.05 5.72 8.88 7.55 
20 17.84 20.39 26.16 18.32 18.66 27.88 
Average 27.77 27.58 28.91 30.49 34.23 34.59 
Std Dev 14.00 12.30 12.86 16.51 13.06 13.66 
p value 0.559 0.001 
 
 
 
SCF =Static conformal field, SCA=Static conformal arc, DCA=Dynamic conformal 
arc 
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7.12 Volume of Brain Receiving 5Gy, 6Gy, 10Gy, 20Gy and 40Gy 
In this study we have collected data on volume of the brain receiving low (5Gy, 6Gy) 
medium (10Gy and 20Gy) and high dose (40Gy). The data on mean doses with 
standard deviation for brain volume receiving 5Gy is presented in Table 7.13 
Table 7-13  Volume of brain in cc receiving the 5Gy dose in three SRT techniques 
Volume of brain in cc receiving 5Gy 
S No SCF SCA DCA 
1 270 342 339 
2 410 506 525 
3 293 308 297 
4 381 526 543 
5 343 379 433 
6 446 552 418 
7 342 516 517 
8 389 484 444 
9 410 544 610 
10 446 752 493 
11 471 576 531 
12 326 447 514 
13 582 1067 1025 
14 595 623 588 
15 456 692 672 
16 714 813 764 
17 313 262 560 
18 347 586 613 
19 539 717 676 
20 590 701 806 
Average volume in cc 433.15 569.65 568.4 
Std Dev ± 118.5 ± 180.24 ± 162.8 
p value 0.001 
 
 
Mean volume with Standard deviation of the brain receiving the 5Gy is 433.15 ± 
118.5 cc, 569.65 ± 180.24cc and 568.4 ± 162.8cc in SCF, SCA and DCA plans 
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respectively. The V5 Brain was the lowest in SCF plans compared to the  other two 
plans SCA and DCA and it was statistically significant (p= <0.001). 
Mean dose of the V6 Brain, V10 Brain, V20 Brain and V40 Brain is presented in the 
Table 7.14 with standard deviation and p values for the three plans. The mean volume 
of the brain receiving 5 and 6Gy were lower in SCF technique compared to SCA and 
DCA techniques, whereas higher volume of brain receiving 10Gy (V10), 20Gy (V20) 
and 40 Gy (V40) was found in SCF technique as compared to SCA and DCA 
techniques. The volume of brain receiving 5, 6, 10, 20 and 40Gy doses were 
comparable in SCA and DCA techniques. 
Table 7-14 Mean volume of the brain in cc receiving 5Gy, 6Gy, 10Gy, 20Gy and 
40Gy 
 DOSE TO THE VOLUME OF BRAIN RECEIVING 5 Gy 
Plan Mean dose Std deviation P value 
SCF 433.15 118.50  
SCA 566.25 180.24 0.001 
DCA 567.00 162.80  
 DOSE TO THE VOLUME OF BRAIN RECEIVING 6 Gy 
Plan Mean dose Std deviation P value 
SCF 419.95 116.83  
SCA 479.10 177.80 0.016 
DCA 476.35 163.30  
 DOSE TO THE VOLUME OF BRAIN RECEIVING 10 
Gy 
Plan Mean dose Std deviation P value 
SCF 363.95 118.29  
SCA 269.25 121.90 0.001 
DCA 267.90 124.20  
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7.13 Treatment Time 
The time taken for treatment delivery was measured for all the three techniques for 
one patient plan for single fraction of radiation (1.8Gy). The measurement was done 
using water phantom on the machine and time was calculated from starting of the 
treatment till completion. The time required for set up of the patient has been assumed 
to be constant. 
In SCF plan, the time taken for single fraction radiation delivery from starting of 
radiation till completion was seven minutes and 40 seconds, whereas time for both 
SCA and DCA plans was similar 8 minutes 20 seconds (difference of 40 seconds was 
found). Though the dose rate was set at 600 MU in all the plans, we found that SCA 
and DCA plans were delivered with dose rate of 136 MU for SCA and DCA 
techniques and 590 MU per minute for SCF plans. 
 DOSE TO THE VOLUME OF BRAIN RECEIVING 20 
Gy 
Plan Mean dose Std deviation P value 
SCF 143.35 103.00  
SCA 115.55 72.78 0.0008 
DCA 113.30 69.85  
 DOSE TO THE VOLUME OF BRAIN RECEIVING 40 
Gy 
Plan Mean dose Std deviation P value 
SCF 143.35 103.00  
SCA 115.55 72.78 0.0008 
DCA 113.30 69.85  
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8 Discussion 
Pituitary adenoma and Craniopharyngioma are benign tumours, anatomically located 
over the sellar region and are closely associated with optic apparatus anteriorly and 
brainstem posteriorly. Stereotactic fractionated radiotherapy delivers highly precise 
and accurate radiation resulting in reduction in the dose to the organs at risk.  SRT has 
been reported as safe and effective in treating Pituitary adenoma and 
Craniopharyngioma. Various Linear accelerator based SRT techniques have been 
defined in the literature (3,4,17). 
It’s necessary to compare techniques in order to find the best possible technique of 
SRT for tumours like Pituitary adenoma and Craniopharyngioma, as these tumours are 
benign and patients survive longer. The techniques were compared in terms of dose 
conformity and homogeneity within the target and quality of target coverage. The 
advantages of each technique is analysed in reducing radiation dose to surrounding 
normal organs at risk. Comparison of volume of the brain receiving low dose of 5Gy 
and 6Gy corresponding to radiation induced second malignancy, medium and high 
dose (10, 20, 40Gy)  which may impair the cognitive functions (76) were analysed 
across all the plans of patient data sets. 
In this study, dosimetric comparison of the three Linear accelerator based stereotactic 
radiotherapy (SRT) techniques, Static Conformal Field (SCF), Static Conformal Arc 
(SCA) and Dynamic Conformal Arc (DCA) for Pituitary adenoma and 
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Craniopharyngioma was conducted on 20 patient data sets. The reference isodose 
volume concurs well with PTV in all the three techniques. 
8.1 Conformity index 
Conformity index estimates the dose conformity to the target and also indirectly 
estimates the dose to the surrounding normal organs. In this study, the conformity 
index for all the data sets in three techniques was <2 accepting the RTOG criteria, 
without any violation of the protocols. The mean conformity indices were slightly 
better in SCF 1.34 (±0.19) and DCA 1.34 (±0.16) than in SCA technique 1.35 (±0.13), 
but this  was not statistically significant (p =0.720). 
Similar study was performed by Ammer et al.,(77) evaluated  the peripheral dose and 
conformity index for three SRT techniques for the intracranial targets for ten patients, 
found mean conformity index of 1.34 (±0.13) for Arcs and 1.4 (±0.09) for Conformal 
fields. The results are similar in the present study. 
In case of SCF the angle of the beam or gantry is manually modified or use of field in 
field approach gives more conformal dose distribution. Similar degree of freedom 
however in case of Arcs may not be possible for individual fields and it depends on 
number and length and distance between each arcs used.  The change in the shape of 
MLCs for every 10 degree gantry rotation would probably support the slightly better 
conformity in DCA plan in the present study. 
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Dosimetric comparison of the stereotactic radiotherapy techniques with   IMRT plans 
for the 4 simulated targets of the cranial tumors by S D Sharma et al.,(50) showed that 
conformity index was better in SCF (mean CI= 0.71) and in DCA (mean CI=0.72) 
plans  than in SCA plans (mean CI of 0.67).  Solberg TD et al., (46) compared 
dynamic arc radiosurgery (SRS) with static field conformal and noncoplanar circular 
arcs on a simulated targets of three overlapping spheres and found that the DCA plan 
was better in dose conformity. 
McCollough et al.,(17) found that conformal shaped fields using 7-11 beams resulted 
in the similar dose distribution as single isocentre circular arc technique.  They also 
noted that, the adjacent normal structures can be easily shielded using conformal 
technique. However the peripheral dose distribution was higher for 7-11 field plans 
than for the circular fields. They also opined that the dynamic MLC would make an 
advantage in reducing the peripheral dose. 
Study by Wiggenraad et al.,(8) comparing IMRT with Dynamic Conformal Arc 
technique for intracranial tumours, reported a mean conformity index ranging from 
1.14 to 1.38 for DCA technique, which is similar to our study. In this study the CI for 
SCF, SCA and DCA plans were comparable, but SCA was slightly inferior 
numerically but it was not statistically significant. 
8.2 Homogeneity index 
Mean homogeneity index was 1.07 (±0.01), to 1.08 (±0.02) and 1.08 (±0.02) in SCF, 
SCA and DCA plans respectively (p=0.033).  In all the plans the homogeneity index 
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was within the RTOG protocol. The homogeneity index was comparatively better in 
the SCF technique. 
Cardinale et al.,(45)compared three linac based stereotactic radiotherapy techniques 
for three intracranial test targets having ellipsoid, hemisphere and irregular target and 
found that CI and HI were higher in arc technique compared to 3D conformal 
technique. But in our study, we found that there was no significant difference in CI 
and HI among the three techniques. 
Study by Wiggenraad et al.(8) comparing IMRT with Dynamic Conformal Arc 
technique for intracranial tumours, reported a mean homogeneity index ranging from 
1.15 to 1.306 for DCA techniques, concluding that DCA technique is more preferred 
for intracranial targets irrespective of shape and size of the targets. 
8.3 Quality of target coverage 
Mean Quality of coverage was within the acceptable limits of RTOG (>90%) in SCF 
and DCA plans, but for SCA plan quality of coverage had minor deviation (80-89%).  
The mean quality of coverage was 85.68% in the case of SCA plan, however it was 
within the acceptable limit with minor deviation (Fig 16). This difference of quality of 
coverage among the three plans was statistically significant (p <0.001). The quality of 
coverage showed minor deviation for 5 SCF plans, 7 SCA plans and 3 DCA plans. 
There was major deviation in 6 SCA plans and no major deviation in SCF and DCA 
plans (Table 7.6). There was no significant correlation between the volume of the 
PTV and quality of coverage. 
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Wiggenraad et al.,(8)  compared IMRT with Dynamic Conformal Arc technique for 
intracranial tumours of different type, shape and size and reported a mean target 
coverage of 99.1% for DCA technique, which is slightly more than our study 93.46 
(±4.51). In the above study, all intracranial tumors irrespective of their location were 
included. The present study included only sellar and suprasellar tumors which are in 
close association with critical structures such as optic chiasm and brain stem. Getting 
optimal target coverage with adequate sparing of these OARs was a challenge in the 
present study. Comparison of the plans individually for CI, HI and Quality of target 
coverage favoured the DCA technique (Table 7.7). When SCF technique was 
compared with SCA there was statistically significant  difference for the Homogeniety 
index and Quality of Coverage but not for Conformity Index.  There was no 
statistically significant difference between DCA, SCA and SCF plans for all the three 
Conformity, Homogeniety indices and Quality of Coverage. Comparison between 
DCA and SCA revealed a statistical difference for quality of coverage (Mean quality 
of coverage was 93.46% in DCA plan and 85.68% in SCA) but not for Conformity 
and Homogeniety indices. Overall, the results were in favour of DCA technique. 
8.4 Dose to organs at risk 
8.4.1 Brainstem and Optic Chiasm 
The average dmax to brainstem was 47.27Gy, 50.07Gy and 48.88Gy in SCF, SCA and 
DCA plans respectively (p=0.019). SCF plan was efficient in achieving the dose 
constraint consistently for 18/20 patients, where as DCA and SCA plans were able to 
achieve the dose constraint in 15/20 patients. The dose to brain stem was better 
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controlled in SCF technique because individual selection of beams minimising the 
entry and exit dose to brain stem was possible. 
The maximum dose to the optic chiasm ranged from 52.99 to 54.81Gy in SCF, 53.16 
to 55.69Gy in SCA and 52.59 to 55.71Gy in DCA plans. Static conformal field plan 
was more efficient in reducing the dose to the optic chiasm as compared to the other 
plans due to the better beam selection as stated above. Wiggenraad et al.,(8) in the 
study comparing IMRT with DCA for intracranial tumours, expressed that sparing the 
optic system is a challenge when the target is close to it and said that the dose up to 
56Gy is acceptable with standard fractionation. None of the patients SRT plan 
exceeded >55Gy in the present study. 
The doses to the optic nerves were well below the constraints in all the cases, none of 
the plans had optic nerve dose >54Gy. Again SCF was better in sparing the optic 
nerves than both the arc techniques. 
8.4.2 Dose to the Brain (V5, V6), (V10, V20) & (V40) 
In this study the volume of the brain receiving the lower dose of 5Gy & 6Gy, 
Intermediate dose of 10Gy & 20Gy and high dose of 40Gy were studied. In both arc 
techniques DCA and SCA, the volume of the brain receiving the low dose (5Gy and 
6Gy) were high compared to the SCF technique which was statistically significant 
(5Gy p=0.001) (6Gy p=0.016). This is explained from the techniques of arc therapy in 
which number of fields will be higher (30-40 depending on the number and length of 
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arc). The small dose from each of these fields is converging to the target resulting in 
high volume of brain receiving low dose. 
Hamilton et al.,(49)  compared the SCF technique with arc therapy in multiple 
intracranial targets, and found that the volume of the normal tissue receiving the lower 
doses (10% of prescription dose) increases with number of fields in the SCF technique 
and multiple arc technique,  the difference was around 1.6 times more in arc technique 
compared to static fields. Also they have reported volume of the normal tissue 
receiving high dose (> 90% of the prescribed dose) was similar in arc and static fields 
using 8-12 fields. Marked difference between volume of the brain receiving the high 
dose and low dose was not found when the number of fields in static conformal 
technique is increased beyond 8. In this study it was found that large volume of brain 
received the low dose (5 and 6Gy) in the arc plans (SCA & DCA) compared to SCF 
plan which was similar to the observation by Hamilton et al., In the present study, it 
was also found that the volume of brain receiving intermediate (10, 20) and high dose 
(40Gy) was higher in SCF plan, with statistical significance (V10 p= 0.001, V20 
p=0.008 and V40 p=0.008) compared to arc plans. 
8.5 Treatment time 
In this study, treatment time was calculated for all the three techniques for one patient 
and the monitor units required to deliver single fraction of radiation was compared for 
the three plans. The median monitor units required to deliver single fraction RT were 
266.5, 265 and 260.5 for SCF, SCA and DCA techniques respectively. Time required 
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in completing single fraction RT was lesser (7 minutes 40 seconds) in SCF plan 
compared to SCA and DCA techniques (8 minute 40 seconds). The numbers of fields 
in SCF were six in this study, and arcs were 4 in both SCA and DCA. 
Similar study on monitor units was performed by Solberg et al.,(78) in a dosimetric 
comparative study of static arc, conformal static fields with dynamic arc radiosurgery, 
in which they found that to achieve more desired dose distributions number of fields 
required in SCF will increase and may consume more time compared to arc 
techniques. They have concluded that use of dynamic arc technique is simple to plan 
and treat. 
The difference in the treatment time between the SCF and Arc techniques may be 
explained based on the dose rate (output in the machine). Dose rate was higher 
590MU per minute in SCF technique as compared to SCA and DCA techniques 
(136MU per minute). 
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9 Conclusions 
The Linac based stereotactic radiotherapy techniques Static Conformal Field (SCF); 
Static Conformal Arc (SCA) and Dynamic Conformal arc (DCA) techniques are 
efficient in delivering highly conformal and homogenous dose to the target in Pituitary 
adenoma and Craniopharyngioma. The Conformity Index and Homogenity Index were 
comparable across the three plans but Quality of target coverage was superior in DCA. 
Dynamic Conformal Arc (DCA) technique was the best technique among the three in 
achieving all the indices. 
Doses to normal organs, Optic Chiasm and Brain stem were better controlled in SCF 
technique than SCA and DCA technique. 
 The volume of the brain receiving 5Gy, 6Gy (low dose) was high in Arc Techniques 
(SCA & DCA) than in SCF technique. The volume of the brain receiving intermediate 
(10Gy and 20 Gy) and high doses (40Gy) were higher in SCF techniques than Arc 
techniques (SCA and DCA). 
Significant difference was not found between the techniques in terms of treatment 
time. 
Further research is needed to show clinical benefit of these dosimetric differences. 
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 Data Record sheet for the study on Dosimetric analysis of the three SRT 
techniques, Static conformal field (SCF), Static Conformal Arc (SCA) & 
Dynamic Conformal Arc (DCA). 
1)  Hospital Number:     
2)  Unique identifying number:    
3)  Age:      
4)  Gender  
5)  Diagnosis  
6)  Prescribed dose of radiation  
7)  Number of fractions of radiation  
8)  Dose per each fraction  
9)  Immobilization devise used  
10)  Dose constraints:  
11)  Dose to Chiasm  
12)  Dose to brain stem  
13)  Dose to left lens  
14)  Dose to right lens  
15)  Dose to left optic nerve  
16)  Dose to right optic nerve  
17)  Reference isodose   
 
SN Variables  SCF SCA DCA 
18 Reference isodose volume    
19 PTV Volume    
20 TV (Tumour volume)    
21 PTV receiving 95% Prescribed dose    
22 Maximum dose (dose maximum)    
23 Maximum dose in Percentage    
24 Minimum dose    
25 Minimum dose in Percentage    
26 Mean dose    
27 Mean dose in Percentage    
28 Conformity index (Conf Index)    
29 Homogeneity index    
30 Quality of coverage    
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31 D5 (Min dose in 5% of PTV)    
32 D95 (Min dose in 95% of PTV)    
33 Maximum Dose to Left Eye    
34 Maximum Dose to Right Eye    
35 Maximum Dose to Brain stem    
36 Maximum Dose to chiasm    
37 Maximum Dose to Left Optic Nerve    
38 Maximum Dose to Right Optic Nerve    
39 Maximum Dose to Left Lens    
40 Maximum Dose to Right Lens    
41 V5 BRIAN (Vol receiving 5 Gy to Brain)    
42 V6 BRIAN (Vol receiving 6 Gy to Brain)    
43 V10 BRIAN (Vol receiving 10 Gy to 
Brain)    
44 V20 BRIAN (Vol receiving 20 Gy to 
Brain)    
45 V40 BRIAN (Vol receiving 40 Gy to 
Brain)    
46 Volume of the brain in cc    
 
Others: 
Any other comments: 
Date:                                                                                    Signature of the investigator 
 
 
 
 
  
S
 N
O
 
H
o
sp
 N
o
 
A
g
e 
G
en
d
er
 
D
ia
g
n
si
s 
P
re
sc
ri
b
ed
 
d
o
se
 
F
ra
ct
io
n
s 
R
IV
-S
C
F
 
R
IV
_
S
C
A
 
R
IV
_
D
C
A
 
P
T
V
 
T
u
m
o
r
 V
o
l 
S
C
F
-P
T
V
 
re
ce
v
in
g
 9
5
%
 
S
C
A
-P
T
V
 
re
ce
iv
in
g
 
9
5
%
 
D
C
A
-P
T
V
 
re
ce
iv
in
g
 
9
5
%
 
S
C
F
 D
O
S
E
 
M
A
X
 
S
C
A
 D
O
S
E
 
M
A
X
 
D
C
A
 D
O
S
E
 
M
A
X
 
S
C
F
 D
M
A
X
 
IN
 
P
E
R
C
E
N
T
 
S
C
A
 D
M
A
 I
N
 
P
E
R
C
E
N
T
 
1 241905F 33 2 PA 5400 30 17.06 14.52 16.69 11.24 4.17 96 96.9 97.9 55.03 54.91 54.96 101.9 101.7 
2 746622F 55 1 PA 5400 30 15.35 16.39 17.86 12.91 4.89 98.8 97.6 99 54.3 54.9 55.17 100.6 101.7 
3 863817D 16 2 CP 5400 30 9.43 9.21 8.93 6.47 2.04 96 96.5 94 55.28 54.6 54.79 102.4 101.6 
4 604422D 11 2 CP 5400 30 20.65 18.78 21.67 12.66 3.81 95.5 91 99.2 54.75 51.19 55.21 101.3 102.6 
5 809043F 36 1 PA 5400 30 10.76 10.38 10.52 7.62 2.53 95.56 96.2 92.4 54.64 55.18 55.4 101.2 102.2 
6 055072G 13 1 PA 5400 30 19.02 19.75 20.59 14.45 5.52 94.7 93.9 96 54.84 55.44 55.1 101.6 102.7 
7 149389G 48 2 CP 5400 30 20.16 16.18 17.16 13.67 5.02 99.7 89.5 93 55.11 54.98 55.03 102 101.8 
8 242503G 13 2 CP 5400 30 16.54 22.01 21.96 15.13 7.2 94.5 96.9 97.5 54.54 55.3 54.87 101 102.4 
9 038442G 38 1 PA 5400 30 17.06 17.56 17.19 14.38 5.68 97.15 96.7 95.18 54.6 55.39 55.38 101.1 102.6 
10 000485G 75 2 PA 5400 30 29.4 34.63 32.23 25.06 11.66 94.6 94.8 93.3 54.69 56 55.4 101.3 103.7 
11 745493F 33 2 PA 5400 30 20.63 20.99 20.84 16.32 7.83 95.7 92.7 91.9 54.88 55 54.82 101.6 101.9 
12 246719C 77 1 PA 5400 30 13.78 15.61 13.36 11.45 4.69 90 97.2 96.6 54.57 54.54 54.52 101.1 101 
13 174879G 47 1 PA 5400 30 66.65 57.3 50.72 41.61 23.62 95.4 96.6 96.8 54.95 55.12 55.12 101.8 102.1 
14 046116G 6 1 CP 5400 30 26.68 30.12 28.7 23.94 10.93 89.6 95.4 95.5 54.79 54.64 54.58 101.5 101.2 
15 481775F 28 2 PA 5400 30 34.43 32.62 27.2 22.02 9.04 95.9 95 98.1 54.69 54.86 54.78 101.3 101.6 
16 252585G 7 2 CP 5400 30 60.59 68.62 63.84 49.15 28.24 95.4 88 95.4 54.79 55.98 55.33 101.5 103.7 
17 225693F 39 2 PA 5400 30 19.18 19.43 17.83 14.51 6.63 97.6 95.7 98.6 55.15 56.87 55.47 102.1 105.3 
18 903424C 67 1 PA 5400 30 20.72 20.65 20.6 11.79 5.04 96 93.4 91.8 54.86 55.46 55.87 101.6 102.7 
19 833446F 32 2 CP 5400 30 26.96 27.96 29.36 23.49 11.53 95.3 90 94.5 55.23 54.97 55.48 102.3 101.8 
20 177376G 6 1 CP 5400 30 42.23 39.9 42.86 34.28 18.37 94.5 91.7 95.8 55.2 56.49 55.33 102.2 104.6 
 
 
D
C
A
 D
M
A
X
 
IN
 P
E
R
C
E
N
T
 
S
C
F
 M
IN
 
D
O
S
E
 
S
C
A
 M
IN
 
D
O
S
E
 
D
C
A
 M
IN
 
D
O
S
E
 
S
C
F
 M
IN
%
 
S
C
A
 M
IN
%
 
D
C
A
 M
IN
5
 
S
C
F
 M
E
A
N
 
D
O
S
E
 
S
C
A
 M
E
A
N
 
D
O
S
E
 
D
C
A
 M
E
A
N
 
D
O
S
E
 
S
C
F
 M
E
A
N
 
D
O
S
E
 I
N
 %
 
S
C
A
 M
E
A
N
 
D
O
S
E
 I
N
%
 
D
C
A
 M
E
A
N
 
D
O
S
E
 I
N
 %
 
S
C
F
 C
I 
S
C
A
 C
I 
D
C
A
 C
I 
 H
I 
S
C
F
 
 H
I 
S
C
A
 
 H
I 
D
C
A
 
1
 D
9
5
 
101.8 48.74 46.09 49.31 90.3 85.4 91.3 53.14 53.12 53.16 98.4 93.8 98.4 1.52 1.29 1.48 1.07 1.07 1.07 51.38 
102.2 49.25 46.85 49.48 91.2 86.8 91.6 52.72 53.26 53.47 97.6 98.6 99 1.19 1.27 1.38 1.06 1.07 1.07 51.3 
101.5 48.68 44.11 49.05 90.1 81.7 90.8 53.25 53.13 53.03 98.6 98.4 98.2 1.46 1.42 1.38 1.08 1.06 1.06 51.01 
102.2 43.62 40.99 49.7 80.8 75.9 92.1 53.16 53.37 53.64 98.4 98.8 99.3 1.63 1.48 1.71 1.06 1.03 1.08 51.84 
102.2 49.7 40.67 46.61 92 75.3 98.59 52.97 53.04 53.21 98.1 98.2 98.5 1.41 1.36 1.38 1.06 1.09 1.08 51.47 
102 48.31 44.2 48.95 89.5 81.9 90.7 53 53.21 53.36 98.1 98.5 98.8 1.32 1.37 1.42 1.06 1.09 1.07 51.71 
101.9 48.99 46 49.12 90.7 85.3 91.41 53.32 52.94 53.88 98.7 98 98.3 1.47 1.18 1.26 1.06 1.08 1.07 51.94 
101.6 46.12 46.43 48.35 85.5 86 89.5 52.77 53.52 53.56 97.7 99.1 98.8 1.09 1.45 1.45 1.07 1.07 1.06 51.12 
102.6 48.67 46.42 48.42 90.1 86 89.7 52.81 52.87 53.19 97.8 95.3 98.5 1.19 1.22 1.20 1.06 1.08 1.08 51.3 
102.6 47.51 45.5 46.32 88 84.3 85.88 52.51 54.04 53.32 97.2 100.1 98.7 1.17 1.38 1.29 1.07 1.09 1.08 51.3 
101.5 47.1 47.42 46.89 87.1 87.8 86.8 53.02 53.25 53.07 98.2 98.6 98.3 1.26 1.29 1.28 1.07 1.08 1.07 51.3 
101 49.08 49.21 47.34 90.09 91.1 87.7 52.3 53.28 52.73 97.1 98.7 97.6 1.20 1.36 1.17 1.07 1.05 1.07 50.89 
102.1 44.54 46.36 47.49 82.5 85.8 87.9 53.13 53.31 52.9 98.4 98.7 98.1 1.60 1.38 1.22 1.07 1.07 1.08 51.3 
101.1 42.7 47.7 47.57 79.1 88.3 88.1 52.71 53.02 52.97 97.6 98.2 98.1 1.11 1.26 1.20 1.08 1.08 1.07 50.76 
101.4 48.92 41 46.83 90.6 75.9 86.71 53.05 53.4 53.13 98.2 98.7 98.4 1.56 1.48 1.24 1.06 1.07 1.06 51.59 
102.5 47.79 40.49 45.95 88.5 75 85.1 52.79 53.41 53.12 97.8 98.9 98.5 1.23 1.40 1.30 1.06 1.11 1.08 51.84 
102.7 49.79 40.3 49.57 92.2 74.6 91.8 53.28 54.17 53.33 98.7 100.3 98.8 1.32 1.34 1.23 1.06 1.10 1.08 51.84 
103.5 43.96 45.81 41.2 81.4 84.8 76.3 53.13 53.55 53.68 98.4 99.2 99.4 1.76 1.75 1.75 1.08 1.08 1.11 50.89 
102.7 47.58 42.57 47.87 88.1 78.8 88.7 53.07 52.98 53.3 98.03 98.1 98.7 1.15 1.19 1.25 1.08 1.10 1.09 51.12 
102.5 41.41 30.86 45.97 77.67 57.17 85.1 52.97 53.89 53.37 98.1 99.8 98.8 1.23 1.16 1.25 1.08 1.12 1.08 51.3 
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51.3 
51.59 
0.73 2.12 1.49 0.75 2.05 1.33 52.34 53.05 52.92 54.81 54.62 54.67 20.67 22.23 28.87 35.4 35.4 36.14 
51.47 51.59 1.03 10.82 12.04 0.72 11.07 9.61 23.45 37.46 29.8 53.35 54.4 54.88 17.37 23.69 22.67 14.98 23.05 20.44 
51.3 51.47 0.86 3.2 2.26 1.14 7.15 6.86 51.71 50.68 50.92 53.58 54.59 54.44 32.39 21.79 26.67 50.35 50.06 51.04 
49.48 51.3 0.7 8.84 10.15 0.66 6.28 4.44 44.88 50.44 49 53.25 53.16 53.06 19.42 23.22 26.49 7.05 28.46 24.42 
50.76 51.12 0.63 4.81 3.94 0.73 5.88 4.35 46.98 45.57 48.03 53.55 53.84 54.35 28.35 12.32 13.21 41.26 37.59 46.89 
51.01 51.3 0.99 9.46 5.11 7.65 12.12 4.96 38.04 41.28 37.3 54.38 54.94 54.56 51.77 52.06 52.49 51.35 52.84 52.65 
51.12 51.3 1.21 7.17 6.86 1.51 5.74 5.87 53.61 53.66 53.74 54.22 53.82 53.87 26.11 25.77 22.17 21.85 25.59 22.98 
51.47 51.84 0.63 0.96 0.78 0.67 1.4 1.13 53.45 54.48 54.24 53.61 54.88 54.5 2.96 7.15 4.36 9.22 22.1 23.62 
51.12 51.3 0.62 2.29 1.44 0.7 1.98 1.63 49.06 50.85 48.5 53.45 53.78 53.88 16.73 17.9 20.3 13.75 21.52 20.66 
51.3 51.3 2.07 11.26 12.59 1.74 12.79 10.67 51.16 53.58 51.74 53.57 55.5 54.6 49.86 49.7 51 49.59 51.98 52.69 
51.12 51.12 1.1 6.32 3.38 1.74 4.14 3.12 53.76 53.31 53.49 54.12 54.83 54.42 27.27 33.34 32.73 24.07 30.33 30.26 
51.84 50.89 1.67 4.2 4.31 1.72 4.1 2.18 25.87 47.98 36.95 54.53 54.56 54.57 36.9 40.42 34.14 26.1 36 27.96 
51.59 51.12 2.23 6.41 14.4 5.62 11.69 15.4 54.39 53.53 54.09 53.62 54.46 54.03 32.58 25.05 30.3 28.59 28.62 30.39 
50.76 51.12 1.36 8.72 7.28 1.36 6.52 5.3 51.96 52.99 54.57 54 54.46 52.71 31 32.57 33.18 44.03 45.77 46.32 
51.47 51.71 1.69 9.27 8.58 3.46 14.38 8.32 52.69 54.56 53.13 53.47 54.56 53.96 44.87 37.53 43.36 49.55 51.45 49.19 
50.42 51.3 5.85 5.61 3.04 7.88 6.84 3.35 53.92 54.85 54.75 52.99 54.61 53.96 49.9 40.86 47.62 50.42 47.63 50.82 
51.71 51.47 1.15 6.29 4.38 1.28 9.7 4.71 53.61 56.82 53.59 53.85 55.51 54.23 28.94 25.25 25.21 49.08 45.11 45.94 
51.12 50.54 0.82 1.86 5.18 0.8 2.07 3.29 26.56 28.32 33.7 54.37 54.83 55.69 15.33 31.75 29.17 19.02 23.65 23.96 
49.84 50.76 1.94 1.07 3.02 2.71 2.11 3.58 53.93 52.7 52.49 53.64 53.73 54.04 5.04 8.54 8.05 5.72 8.88 7.55 
50.65 51.12 1.61 4.36 8.57 1.69 8.79 8.43 54.11 55.46 54.67 53.1 54.96 54.18 17.84 20.39 26.16 18.32 18.66 27.88 
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0.35 0.42 0.39 0.32 0.42 0.39 270 342 339 261 272 272 234 163 164 85 68 74 24 22 23 95.05 89.89 96.11 
0.38 8.01 9.02 0.35 7.03 5.34 410 506 525 397 372 385 346 189 193 66 75 68 25 28 68 96.00 91.37 96.42 
0.34 0.34 0.35 0.36 0.54 0.35 293 308 297 283 279 272 245 153 163 40 44 50 14 13 14 94.84 86.00 95.58 
0.3 5.06 6.48 0.33 2.14 1.81 381 526 543 367 421 424 256 228 241 119 85 88 51 38 38 85.05 79.89 96.95 
0.28 1.08 0.59 0.32 1.19 0.48 343 379 433 323 257 301 171 111 114 117 40 43 19 17 17 96.84 79.26 103.78 
0.45 4.63 2.5 0.67 5 2.07 446 552 418 435 441 381 389 221 215 76 74 104 29 29 33 94.21 86.21 95.47 
0.34 0.51 0.5 0.34 0.47 0.42 342 516 517 331 429 426 296 238 239 98 79 80 35 31 30 95.47 89.79 96.22 
0.31 0.42 0.35 0.34 0.45 0.42 389 484 444 369 448 375 270 275 244 175 135 138 33 35 44 90.00 90.53 94.21 
0.3 1.21 0.51 0.33 1.09 0.38 410 544 610 398 434 458 355 194 196 82 87 72 25 28 26 94.84 90.53 94.42 
0.76 7.29 7.05 0.56 8.05 2.98 446 752 493 434 661 411 369 324 239 110 110 116 43 44 46 92.63 88.74 90.40 
0.53 1.36 1.19 0.56 0.64 1.38 471 576 531 458 445 437 413 187 191 81 74 79 28 27 28 91.68 92.42 91.37 
0.36 2.17 0.96 0.51 2.11 0.55 326 447 514 317 401 414 285 242 183 73 57 47 19 16 16 94.83 95.89 92.32 
0.95 1.94 4.75 0.97 5.45 5.21 582 1067 1025 569 949 921 531 492 512 304 203 181 105 86 81 86.84 90.32 92.53 
0.54 3.14 1.63 0.56 2.83 1.51 595 623 588 576 507 459 496 295 295 131 154 152 50 54 53 83.26 92.95 92.74 
0.61 5.82 3.13 0.73 8.56 3.58 456 692 672 444 533 556 414 252 252 102 110 90 40 42 38 95.37 79.89 91.27 
1.31 0.85 0.9 1.3 0.87 1.05 714 813 764 699 757 714 632 604 562 424 337 329 109 120 123 93.16 78.95 89.58 
0.48 1.02 2.51 0.48 2.25 2.04 313 262 560 305 250 451 285 190 186 86 84 58 21 21 22 97.05 78.53 96.63 
0.29 0.74 3.13 0.33 0.9 1.37 347 586 613 337 448 523 310 234 289 136 104 119 32 30 29 85.68 89.26 80.32 
0.68 0.51 0.46 0.64 0.57 0.47 539 717 676 523 638 609 462 360 392 199 154 152 54 52 50 92.74 82.95 93.37 
0.9 1.26 3.36 0.93 0.96 1.98 590 701 806 573 640 738 520 433 488 363 237 226 76 63 74 81.76 60.18 89.58 
 
